



Are there sleep-specific phenotypes in patients with Chronic Fatigue Syndrome? A cross-sectional polysomnography analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002999
Article Type:	Research
Date Submitted by the Author:	05-Apr-2013
Complete List of Authors:	Gotts, Zoe; Northumbria University, Northumbria Centre for Sleep Research Deary, Vincent; Northumbria University, Psychology Newton, Julia; Newcastle University, Institute for Ageing and Health van der Dussen, Donna; VermoeidheidCentrum Nederland bv, Fatigue Service de Roy, Pierre; VermoeidheidCentrum Nederland bv, Fatigue Service Ellis, Jason; University of Northumbria, Northumbria Centre for Sleep Research
Primary Subject Heading:	Patient-centred medicine
Secondary Subject Heading:	Patient-centred medicine, General practice / Family practice, Evidence based practice
Keywords:	INTERNAL MEDICINE, SLEEP MEDICINE, STATISTICS & RESEARCH METHODS, MENTAL HEALTH

SCHOLARONE™
Manuscripts

1
2
3 Are there sleep-specific phenotypes in patients with Chronic Fatigue Syndrome? A cross-sectional
4
5 Polysomnography analysis
6
7
8

9
10 Zoe M. Gotts MSc^a, Vincent Deary PhD^a, Julia Newton MD^b, Donna van der Dussen MD^c, Pierre de
11
12 Roy MD^c, Jason G. Ellis PhD^{a*}
13

14
15
16 * Corresponding Author

17 Dr Jason G Ellis
18 Northumbria Centre for Sleep Research
19 School of Life Sciences
20 Northumbria University
21 138 Northumberland Building
22 Newcastle-upon-Tyne
23 NE1 8ST
24 Jason.ellis@northumbria.ac.uk
25 +44(0)1912273081
26
27
28
29
30
31
32
33
34
35
36
37

- 38
39 a) Northumbria Centre for Sleep Research, Northumbria University, Newcastle, UK
40 b) Institute for Ageing and Health, Newcastle University, Newcastle, UK
41 c) VermoeidheidCentrum Nederland bv, Lelystad, Netherlands
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Despite sleep disturbances being a central complaint in patients with Chronic Fatigue Syndrome (CFS), evidence of objective sleep abnormalities, from over 30 studies, is inconsistent. The present study aimed to identify whether sleep-specific phenotypes exist in CFS and explore objective characteristics that could differentiate phenotypes, whilst also being relevant to routine clinical practice.

Design: A cross-sectional, single-site, study.

Setting: A fatigue clinic in the Netherlands

Participants: A consecutive series of 343 'otherwise healthy' patients meeting criteria for CFS, according to the Fukuda definition.

Measures: Patients underwent a single night of polysomnography (all-night recording of Electroencephalography, Electromyography, Electrooculography, Electrocardiogram and Respiration) that were hand-scored by a researcher blind to diagnosis and patient history.

Results: Of the 343 patients, 104 (30.3%) were identified with a Primary Sleep Disorder explaining their diagnosis. A hierarchical cluster analysis on the remaining 239 patients resulted in four sleep phenotypes identified at saturation. Of the 239 patients, 89.1% met quantitative criteria for at least one objective sleep problem. A one-way ANOVA confirmed distinct sleep profiles for each sleep phenotype. Relatively longer sleep onset latencies, longer REM latencies, and smaller percentages of both Stage 2 and REM characterized the first phenotype. The second phenotype was characterised by more frequent arousals per hour. The third phenotype was characterised by a longer Total Sleep Time, shorter REM Latencies, and a higher percentage of REM and low percentage of wake time. The final phenotype had the shortest Total Sleep Time and the highest percentage of wake time and wake after sleep onset.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: The results highlight the need to routinely screen for Primary Sleep Disorders in clinical practice and tailor sleep interventions, based on phenotype, to patients presenting with CFS. The results are discussed in terms of matching patients' self-reported sleep to these phenotypes in clinical practice.

For peer review only

Article Focus

- Despite 85-90% of patients with CFS reporting unrefreshing sleep, previous research has been unable to reliably identify specific irregularities in objective sleep
- To explore the possibility that sleep problems in this population are not homogeneous and that several sleep-specific phenotypes exist in this population which are amenable to different treatment approaches

Key Messages

- Over 30% of individuals with CFS, met diagnostic criteria for Sleep Apnoea or Periodic Limb Movement Disorder that could explain their current diagnosis.
- The sleep in those with CFS, without Sleep Apnoea or Periodic Limb Movement Disorder, centred around four specific sleep-disturbed phenotypes with 89.1% demonstrating quantitative criteria for insomnia or hypersomnolence.
- Each sleep-phenotype in CFS comprised objective characteristics that could be assessed and differentiated using patient's self-reports in primary care.

Strengths and Limitations:

- This is the first study to suggest, and identify, specific sleep-phenotypes in a large sample of patients with CFS.
- The objective findings can be easily translated and applied in routine primary care.
- A limitation is the use of a single-night of Polysomnography.

INTRODUCTION

Chronic Fatigue Syndrome (CFS), as defined by the international consensus definition¹ is a condition characterised by profound fatigue, of definite onset, which has persisted for at least 6 months, and causes substantial disruption to the individual's daily functioning. In addition to fatigue, at least four other key symptoms are required to fulfil diagnostic criteria, including muscle and joint pain, headache, cognitive dysfunction and unrefreshing sleep. Thus defined, CFS affects between 0.23-2.6% of the adult population²⁻⁴. There are several theories as to the pathogenesis of CFS. However it is likely the development and maintenance of CFS is multifactorial. Predisposing factors include a general propensity to both emotional and physical distress, history of abuse, being more than usually physically active, and being perfectionist⁵⁻⁸. Precipitating events include viruses such as glandular fever and major life events⁹⁻¹⁰. Several factors appear to be involved in the maintenance of symptoms. Physiologically evidence suggests dysregulation of the hypothalamic pituitary adrenal (HPA) axis, increased cytokine production and HPA responsiveness to cytokines¹¹⁻¹², and autonomic dysfunction¹³⁻¹⁴. Two studies also highlight the importance of illness beliefs and behaviours¹⁵⁻¹⁶. Individuals who adopt all or nothing coping styles in response to symptoms (i.e. push on through until they crash out) and attribute broad ranges of everyday symptoms to their illness are more likely to develop CFS post-virally. In sum, research suggests in CFS multiple processes in distinct domains, such as physiology, illness beliefs, inconsistent activity, sleep disturbance, medical uncertainty, and lack of guidance, can interact to maintain or exacerbate symptoms¹⁷.

As mentioned above, unrefreshing sleep is one key diagnostic characteristic of CFS¹. It is also one of the most common symptom complaints¹⁸⁻¹⁹ with 87-95% of patients reporting sleep difficulties²⁰ that do not improve over the course of the illness²¹. Where the purpose of sleep is subject to intense debate, its importance to human health and well-being is undeniable. Examinations of individuals deprived or restricted of sleep consistently demonstrate deteriorations in mood, cognition, and

1
2
3 performance²². The purpose of each different sleep stage is also unclear although it is generally
4
5 agreed that the lighter stages of sleep (stage 1 sleep and stage 2 sleep) afford transitions between
6
7 wakefulness and sleep and then between slow wave sleep (SWS) and Rapid Eye Movement sleep
8
9 (REM). SWS and REM are believed to confer recuperative, restorative, and learning properties for
10
11 the individual (e.g. the secretion of growth hormone, consolidation of memory)²³⁻²⁴. Therefore, the
12
13 proportion of each sleep stage and timing of entry into each sleep stage, SWS and REM in particular,
14
15 are important for the long-term maintenance of human physical and mental health.
16
17

18
19
20 Symptoms such as unrefreshing sleep may not only be markers of CFS but may also serve to
21
22 maintain it. For instance there may be reciprocal links between sleep quality, sleep-wake regulation
23
24 and fatigue. There is evidence of this, for instance, studies have shown that adopting activity and
25
26 sleep management strategies improves HPA axis functioning as measured by cortisol levels²⁵. This
27
28 suggests further investigation of sleep disturbance of CFS is of more than academic importance but
29
30 may highlight new avenues for intervention. From a clinical perspective it is also important to study
31
32 sleep more thoroughly in CFS as it may highlight some areas of diagnostic ambiguity. For instance
33
34 previous studies have shown sleep disorders (notably obstructive sleep apnoea) are occasionally
35
36 identified during PSG assessments with CFS patient cohorts²⁶⁻²⁹.
37
38

39
40
41 Although over 30 Polysomnographic (PSG) studies on individuals with CFS exist, conclusive
42
43 statements about the type of sleep abnormalities in this population are difficult. Few studies report
44
45 a full characterisation of both sleep continuity (the timing, efficiency, and amount of sleep obtained)
46
47 and sleep architecture (amount of each sleep or wake stage and the timing of transitions to each
48
49 sleep stage), with some studies providing no PSG data at all^{26, 30-34}. Moreover, reporting practices
50
51 differ widely making interpretation and comparisons difficult (e.g. studies report the percentage of
52
53 each sleep and wake stage as an index of Sleep Period Time, Total Sleep Time or even Time in Bed²⁸⁻
54
55
56
57
58
59
60

1
2
3 29; 35-42 whilst others report minutes of each stage⁴³⁻⁴⁷. What can be concluded from previous PSG
4
5 studies is in each study deviations from 'normal sleep' exist but there is no consistent pattern. For
6
7 example, where two studies⁴³⁻⁴⁴ report poor sleep efficiencies and 'normal range' REM latencies,
8
9 others^{35-36,44} found 'normal range' sleep efficiencies and short REM latencies and others still report a
10
11 normal sleep efficiency and a long REM latency⁴⁰ or poor sleep efficiency and long REM latencies⁴⁷.
12
13 Moreover, the picture remains unclear after controlling for the severity of patients' self-reported
14
15 sleep complaints⁴⁸⁻⁴⁹. Although differences in protocol, definitional criteria, and reporting criteria
16
17 may, to some extent, explain these differences, an alternative explanation is sleep difficulties in
18
19 individuals with CFS are not homogenous and various sleep phenotypes exist in this population.
20
21
22
23
24
25

26 To clarify the specific characterisation of sleep in CFS, the current study examined polysomnographic
27
28 data for a single night of sleep in a large group of CFS patients, to determine whether specific sleep
29
30 disturbances exist in this group, and if so, are these consistent across all patients.
31
32
33
34
35

36 METHOD

37
38
39 A cross-sectional, single-site, observational study was undertaken on a consecutive series of 343
40
41 patients (Mean age 37.21±12.42 years; 72 males 271 females) referred for a single-night
42
43 polysomnographic (PSG) study at a fatigue clinic in the Netherlands. The referral criteria for PSG
44
45 investigation were that the patient, a) met diagnostic criteria for CFS according the Fukuda definition
46
47 (1), b) they were drug-free for at least two-weeks prior to the overnight study, and c) their
48
49 symptoms could not be explained by a physical or psychological illness (e.g. anxiety or depression).
50
51 Patients gave informed consent to take part in the study and then were interviewed and medically
52
53 screened for the referral criteria by a registered physician and a registered psychiatrist.
54
55
56
57
58
59
60

Patients arrived at the clinic two hours before normal bedtime for electrode placement and bio-calibration. The PSG montage comprised a standard 10/20 (i.e. F₄-M₁, C₄-M₁, O₂-M₁ and C_z with backups at F₃-M₂, C₃-M₂, O₁-M₂ and F_{p2}). Additional channels were used for EOG (E₁ and E₂ referenced to M₂), EMG (chin and anterior tibialis placements), ECG, and airflow, effort, body position, and oximetry (via pulse oximeter). Filter settings were set to American Academy of Sleep Medicine⁵⁰ guidelines (e.g. low 0.3Hz / high 35Hz for EEG and EOG) with a sampling rate of 500Hz. Impedances were maintained below 5KΩ. Participants were allowed to retire to bed when they wished and left to naturally wake in the morning. Scoring was conducted manually by a registered BRPT certified technician at 30-second epochs, according to AASM guidelines. The scorer was blind to the aims of the study. The mean recording period was just over 8 hours (508.5 ± 63.11 minutes). Descriptions of all sleep variables are detailed in Table 1.

Table 1: Description of sleep variables

Total Sleep Time (minutes)	Amount of time asleep
Sleep Onset Latency (minutes)	Length of time from lights out to first episode of stage 2 sleep
Wake After Sleep Onset (minutes)	Number of minutes of recorded wake following first episode of stage 2 sleep
Number of Awakenings (over TSP)	Number of wake bouts following first episode of stage 2 sleep
Number of Arousals	Number of arousals over the entire sleep period
Sleep Efficiency	Percentage of overall time spent in bed asleep
REM Latency	Length of time to first REM stage
AHI Index	Number of apnoea or hypopnea events per hour of sleep
% N1 (of TST)	Percentage of recorded stage 1 sleep over the total time asleep
% N2 (of TST)	Percentage of recorded stage 2 sleep over the total time asleep
% N3 (of TST)	Percentage of recorded slow wave sleep over the total time asleep
% REM (of TST)	Percentage of recorded Rapid Eye Movement sleep over the total time asleep
% WAKE (of TSP)	Percentage of recorded wake over the whole sleep period (from lights out to lights on)

RESULTS

An initial examination of the Apnoea Hypopnoea Index (AHI) and Periodic Limb Movements (PLM's) indices indicated that 104 (43 males and 61 females) of the original 343 referrals (30.3%) met AASM

1
2
3 criteria for either sleep apnoea (AHI \geq 15; n = 101) or a periodic limb movement disorder (PLMs \geq 5;
4
5 n =17) (14 participants met criteria for both disorders). The overall sleep profile of the remaining 239
6
7 patients (Mean Age 34.4 \pm 11.84; 210 females and 29 males) was highly variable indicating the
8
9 presence of phenotypes (Figure 1).
10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Insert Figure 1 Here

A hierarchical cluster analysis, using Ward's method, was undertaken to determine the number of groups (clusters) within the remaining 239 patients. Prior to the cluster analysis a correlation matrix was examined to avoid multicollinearity influencing the cluster model. On this basis four variables were excluded (Height, Weight, Sleep Efficiency, and number of Spontaneous Arousals per hour) for having correlation coefficients with one or more variables above $r = .8$. The final grouping variables included in the cluster analysis were; age, sex, BMI, AHI's, PLM index, Number of Awakenings, Number of Arousals per hour, Total Sleep Time (TST), Sleep Latency (SL), Wake After Sleep Onset (WASO), percentage of %N1 (stage 1 sleep) of TST, %N2 (stage 2 sleep) of TST, %N3 (SWS) of TST, %WAKE of TST, %REM of TST, and REM Latency (REML). The Euclidean squared distance measure of similarity was used to group patients according to the included variables.

There were 6 clustering iterations overall (going from 8 clusters to 2). The fourth iteration was chosen as saturation point as it was where the agglomeration schedule and dendrogram had the highest reduction in the number of groupings (from six groups to four groups = reduction of 33%) whilst retaining at least 5% of the total sample size in each group (i.e. $n \geq 11$). This latter rule was chosen to afford sufficient power for inferential data analysis to occur.

A one-way ANOVA was undertaken on the four groups to determine which sleep variables significantly differentiated the groups. There were no overall differences between the groups on age ($F(3,235)=1.95, p=.12$) or BMI ($F(3,235)=.82, p=.48$) but a significant sex difference was observed ($\chi^2(3)=10.54, p<.02$). On inspection of the sex frequencies in each group, there was a significantly higher ratio of males to females (35.71% male) in the first group compared to the other three groups (17.65%, 9.59%, and 4.17% male respectively) although due to the number of males in the overall sample (12.13%) this is likely to be artefact. In relation to the polysomnography variables there were no group differences in the number of arousals per hour or AHI index scores (PLMs were not included as less than 10% of the total sample had a PLM index), but significant differences were observed on all the other sleep variables (Table 2).

Table 2: Characteristics of sample of individuals with CFS

Grouped Variable Clusters	Group 1 (N = 14)	Group 2 (N = 55)	Group 3 (N = 146)	Group 4 (N = 24)	F	p
Demographics						
Age	35.79 (12.39)	37.29 (12.72)	32.99 (10.82)	35.54 (14.49)	1.95	n.s.
BMI	24.86 (5.68)	23.85 (4.63)	23.41 (4.03)	22.81 (3.86)	0.82	n.s.
Sleep Variables						
Total Sleep Time (minutes)	270.95 (41.85)ab	387.03 (46.1)acd	473.21 (45.82)bce	264.15 (74.43)de	188.1	p<.001
Sleep Onset Latency (minutes)	107.79 (42.09)abc	30.97 (29.13)ad	19.17 (14.71)bd	28.94 (27.54)c	67.26	p<.001
Wake After Sleep Onset (minutes)	75.79 (39.35)ab	82.12 (45.25)cd	35.45 (25.39)ace	180.2 (58.48)bde	119.7	p<.001
Number of Awakenings (over TSP)	15.21 (8.06)	14.75 (11.62)ab	9.54 (5.85)a	16.96 (9.26)b	10.52	p<.001
Number of Arousals	3.57 (9.21)	10.91 (23.01)	6.2 (15.26)	1.38 (4.13)	2.24	n.s.
REM Latency	173.22 (55.03)abc	57.71 (34.31)ad	47.01 (28.22)be	84.46 (48.21)cde	63	p<.001
AHI Index	3.43 (3.46)	4.58 (4.39)	4.73 (4.04)	3.54 (4.19)	0.92	n.s.
% N1 (of TST)	21.84 (13.36)a	14.35 (9.14)b	12.55 (7.37)ac	24.22 (14.82)bc	14.15	p<.001
% N2 (of TST)	27.57 (13.15)ab	38.82 (12.36)a	38.44 (12.14)b	36.95 (13.66)	3.46	p<.02
% N3 (of TST)	44.46 (20.45)abc	31.07 (11.05)a	31.78 (12.41)b	29.28 (16.42)c	4.64	p<.004
% REM (of TST)	6.11 (4.58)abc	15.16 (5.47)ad	17.19 (5.57)be	9.65 (6.35)cde	26.46	p<.001
% WAKE (of TSP)	60.32 (21.09)abc	25.75 (11.61)ade	11.03 (6.16)bfd	75.26 (22.92)cef	271.6	p<.001

First Phenotype

The first phenotype comprised 14 patients with the longest Sleep Onset and REM Latencies and the highest percentage of SWS. Moreover, this group had the lowest percentages of both Stage 2 sleep and REM sleep. Statistically; this phenotype differed from the other three groups in terms of longer Sleep Onset and REM latencies, and a lower percentage of REM.

Second Phenotype

The second phenotype comprised 55 patients with the highest percentage of Stage 2 sleep and the highest number of arousals per hour although neither of these variables statistically separated them from all three other phenotypes.

Third Phenotype

The third phenotype comprised 146 patients with the highest Total Sleep Time and percentage of REM. Additionally, this group demonstrated the shortest Sleep Onset and REM Latencies, lowest wake after sleep onset and percentages of wake time and Stage 1 sleep, and the lowest number of awakenings. Statistically, Total Sleep Time, percentage wake, and wake after sleep onset differentiated this phenotype from each of the others.

Fourth Phenotype

The fourth phenotype comprised 24 patients who demonstrated the highest wake after sleep onset, percentages of wake and Stage 1 sleep, and the highest number of awakenings. This group were also the lowest in terms of Total Sleep Time, number of arousals per hour, and percentage of SWS. Statistically, only wake after sleep onset and percentage of wake differentiated this group from each of the others.

DISCUSSION

The aim of the study was to determine whether specific sleep phenotypes existed in patients with CFS. A large consecutive series of patients, meeting criteria for CFS, underwent a single night of polysomnography to determine the presence or absence of distinct sleep phenotypes. The first finding, over 30% of individuals meeting diagnostic criteria for CFS also demonstrated a Primary Sleep Disorder (sleep apnoea or PLMD) is important and underscores the need to assess for Primary Sleep Disorders (PSDs) in CFS populations. As recommended treatment strategies for some PSDs differ considerably from those for CFS (e.g. Continuous Positive Airway Pressure for apnoea vs. sleep management strategies in CFS) it is important to direct the individual to, or adjunct, appropriate care pathways as soon as possible. This finding also questions the ability to differentiate fatigue associated with sleep apnoea or PLMD from that associated with CFS. Here family members and/or carers may be helpful for diagnosis sensitivity as they are likely to be aware of nocturnal breathing disturbances (i.e. heavy snoring, gasping or pauses in breathing).

The overall PSG results (after excluding sleep apnoea and PLMD) confirm objective sleep difficulties in patients with CFS. When comparing percentages of each sleep stage in 'normal' adult sleepers (i.e. $\leq 5\%$ wake, between 2-5% stage 1, between 45-55% stage 2, between 13-23% SWS, and between 20-25% REM⁵¹) to the present sample this group fall outside the range on all these variables. The present sample are spending more time awake and in the lighter stages of sleep (stage 1 and 2 sleep), and less time in deeper sleep stages of sleep (i.e. stage 2 sleep and SWS) and in REM. Further, using the quantitative benchmarks of sleep disturbance outlined by Edinger⁵² it can be seen that where sleep efficiency and sleep latencies appear to be on the cusp of 'normal' sleep in the present sample (85% sleep efficiency is considered normal and a sleep latency of ≥ 30 denotes a sleep problem), wake after sleep onset appears to be almost twice as long as is considered problematic

1
2
3 (≥ 30 minutes tends to denote a sleep problem). Together, these findings indicate that sleep is an
4
5 objectively verifiable problem for patients with CFS that should be addressed clinically.
6
7
8
9

10
11 The cluster analysis identified, at saturation, four sleep phenotypes. The dendrogram identified two
12
13 groups partially related (i.e. groups one and four) and two that were largely independent (i.e. groups
14
15 two and three). This configuration was confirmed by the ANOVA showing statistically significant
16
17 differences in sleep continuity and architecture variables between the groups. That said, where
18
19 statistical significance and relative characterisation (e.g. highest in variable WX and Y and lowest in
20
21 variable Z) are important in understanding between-group differences the more salient question is
22
23 whether these four groups are clinically relevant in terms of specific sleep treatments in patients
24
25 with CFS. The use of different pharmacological agents (benzodiazepines, z-hypnotics, or stimulants)
26
27 or therapeutic interventions (i.e. Cognitive Behavioural Therapy for Insomnia or behavioural
28
29 modification strategies) has been shown to have differential effects on specific aspects of sleep
30
31 continuity and architecture. For example, zolpidem appears to have a better impact on the number
32
33 of awakenings and perceived quality of sleep compared to nitrazepam, and lormetazepam appears
34
35 better in reducing sleep latencies than zopiclone⁵³. As such tailoring treatment options to the
36
37 presenting sleep problems in this population is likely to be more effective (Table 3).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3: Characteristics (statistical and phenomenological) of patients with CFS

Sleep Phenotype	Central Differential Features	Associated Diagnostic Features	How this may present subjectively
1	Long Sleep Onset Latency Long REM Latency High amounts of Slow Wave Sleep Low amounts of REM	Low amounts of Stage 2 Sleep	Problems in getting off to sleep but when asleep few awakenings. The Sleep that is obtained is of normal quality.
2		High number of arousals per hour High amounts of Stage 2 Sleep	No difficulties in getting off to sleep and few awakenings but feelings or evidence of a 'restless' nights sleep
3	High Total Sleep Time Low amounts of time awake during the night Low number of wake periods during the night	High amounts of REM Sleep Short Sleep Onset Latency Low number of Awakenings Short REM Latencies Low amounts of Stage 1 Sleep	No difficulties in getting off to sleep and few awakenings but feelings of being unrefreshed on waking despite a significant amount of time in bed asleep.
4	Highest number of wake periods during the night Highest amounts of time awake during the night	Low Total Sleep Time Low number of arousals per hour during the night Low amounts of Slow Wave Sleep	Short sleep duration and although no difficulties getting off to sleep lots of awakenings for significant periods of time. Also increased feelings of daytime sleepiness.

Another, albeit related, consideration is the presence within the final sample of PSDs for which PSG is either not routinely recommended or where stand-alone it is insufficient for a definitive diagnosis⁵⁰. Most relevant to the present sample are insomnia disorder and hypersomnolence disorders. Interestingly, groups one and four appear to be characterised by insomnia-like symptoms (i.e. difficulties initiating sleep or maintaining sleep) whereas groups two and three appear to share overlapping characteristics with disorders characterised by poor sleep quality (Table 2). In relation to group three there is some overlap with hypersomnolence disorders (the term hypersomnolence will replace hypersomnia under the DSM-5) as 14 patients (9.59%) slept for nine hours or longer and eight patients (5.48%) demonstrated the main polysomnographically defined symptom of narcolepsy (i.e. a REM Latency of less than 15 minutes). For group two there is no obvious overlap with a specific DSM-5-defined sleep disorder although as Stage 2 sleep has been associated with hormonal and autonomic regulation⁵⁴ increased amounts are likely to relate to both higher levels of autonomic

1
2
3 and cortical arousal inhibiting deep sleep. As such, a PSG study with adjunct sleep history interviews,
4
5 sleep diaries, actigraphy, and/or Multiple Sleep Latency Test or Maintenance of Wakefulness test
6
7 would be valuable tools in determining whether these groups share all the diagnostic features of
8
9 each PSD.
10

11
12
13
14
15 The findings from the present study should be viewed with limitations in mind. There was no control
16
17 group to determine the extent to which the four phenotypes exist in the general population. That
18
19 said, with approximately 6% of the population meeting diagnostic criteria for insomnia⁵⁵ and 5%
20
21 meeting diagnostic criteria for hypersomnia⁵⁶ the present data do not reflect this with 213 of the 239
22
23 (89.1%) participants, without apnoea or PLMS, meeting at least one quantitative criteria for
24
25 insomnia or hypersomnia. It could also be argued that a single night of polysomnography may not be
26
27 enough to capture the sleep of patients with CFS due to the first-night-effect⁴³. That said, where Le
28
29 Bon and colleagues demonstrated significant differences between nights one and two in a cohort of
30
31 individuals with CFS, these differences were not largely evident in the sleep architecture and many
32
33 differences in the sleep continuity variables disappeared after those with psychiatric illnesses were
34
35 excluded from the analysis. Interestingly, over 25% of Le Bon et al's⁴³ sample also demonstrated an
36
37 'inverse first-night-effect' whereby they slept better on the first night compared to the second. This
38
39 issue of the first-night-effect in CFS is further complicated by other studies which have shown no
40
41 such effect in this population²⁹. It is likely that inconsistencies in the first-night-effect reflect typical
42
43 night-to-night variability⁵⁷⁻⁵⁹ in addition to situation-specific factors relating to the PSG on the first
44
45 and second nights. What would be ideal, albeit expensive, is a PSG study over several nights (e.g. at
46
47 least fourteen continuous nights are suggested for insomnia⁶⁰) to ensure these issues are accounted
48
49 for. That said, what may be more practical is to determine how information from the present study
50
51 can inform, in conjunction with other assessments, actual clinical practice. One suggestion is, ideally
52
53 after ruling out PSDs, individuals should be interviewed about their sleep (usually over the last
54
55
56
57
58
59
60

1
2
3 month) and provide a sleep diary. This information would provide a subjective account that could be
4
5 matched to the four phenotypes (as in Table 3) to inform treatment.
6
7
8
9

10
11 Overall, the results suggest a significant overlap between CFS and a variety of symptoms of sleep
12
13 disturbance. One night of PSG is sufficient to tease apart, and exclude, those with apnoea and
14
15 periodic limb movement disorders from four other distinct sleep phenotypes in patients with CFS.
16
17 Interestingly, these four phenotypes tend to mirror symptoms related to sleep quality and quantity
18
19 that are amenable to different treatment strategies. As such, clinicians tailoring sleep-based
20
21 interventions for patients with CFS should be mindful of these phenotypes.
22
23
24
25
26

27 Contributions – All authors (JGE, ZMG, VD, JLN, PdR, DD) were involved in the design of the study.

28
29 PdR and DD conducted the study and JGE and ZMG analysed the data. The first draft was written by
30
31 JGE, JLN, VD and ZMG and was edited by all authors. All authors approved the final version of the
32
33 manuscript.
34
35
36
37
38

39 Funding – This research was not funded
40
41
42

43 Competing Interests – None
44
45
46

47 Provenance and peer review – Not commissioned; externally peer reviewed
48
49
50

51 Data sharing statement – No additional data are available
52
53
54
55
56
57
58
59
60

REFERENCES

- (1) Fukuda, K., Straus, S. E., Hickie, I., et al. (1994). The chronic fatigue syndrome - a comprehensive approach to its definition and study. *Annals of Internal Medicine*, 121(12), 953-959.
- (2) Wessely, S., Chalder, T., Hirsch, S., Wallace, P., & Wright, D. (1997). The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: A prospective primary care study. *American Journal of Public Health*, 87(9), 1449-1455.
- (3) Jason L, Richman J, Rademaker A et al. (1999). A community based study of chronic fatigue syndrome. *Arch Intern Med*, 159: 2129–2137.
- (4) Reyes, M., Nisenbaum, R., Hoaglin, et al. (2003). Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. *Archives of internal medicine* 163(13), 1530-1536.
- (5) Kato, K., Sullivan, P. F., Evengard, B., & Pedersen, N. L. (2006). Premorbid predictors of chronic fatigue. *Archives of General Psychiatry*, 63(11), 1267-1272.
- (6) Taylor R, Jason L (2001). Sexual abuse, physical abuse, chronic fatigue, and chronic fatigue syndrome: a community-based study. *J Nerv Ment Dis* 189: 709–715.
- (7) Harvey, S. B., Wadsworth, M., Wessely, S., & Hotopf, M. (2008). Etiology of chronic fatigue syndrome: testing popular hypotheses using a national birth cohort study. *Psychosomatic Medicine*, 70(4), 488-495.
- (8) Deary, V. & Chalder, T. (2010). Personality and perfectionism in chronic fatigue syndrome: a closer look. *Psychology & Health*, 25(4), 465-475.
- (9) Buchwald, D. S., Rea, T. D., Katon W. J., Russo, J. E., & Ashley, R. L. (2000). Acute infectious mononucleosis: characteristics of patients who report failure to recover. *The American Journal of Medicine*, 109 (7), 531-537.
- (10) Hatcher, S. & House, A. (2003). Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study. *Psychological Medicine*, 33(7), 1185-1192.

- 1
2
3 (11) Gaab, J., Rohleder, N., Heitz, V., et al. (2005). Stress-induced changes in LPS-induced pro-
4
5 inflammatory cytokine production in chronic fatigue syndrome. *Psychoneuroendocrinology*,
6
7 30, 188–198.
8
9
10 (12) Cho H. J., Hotopf, M., & Wessely, S. (2005). The placebo response in the treatment of chronic
11
12 fatigue syndrome: a systematic review and meta-analysis. *Psychosomatic Medicine*, 67(2),
13
14 301-13.
15
16 (13) Jones, D. E., Hollingsworth, K. G., Taylor, R., Blamire, A. M., & Newton, J. L. (2010).
17
18 Abnormalities in pH handling by peripheral muscle and potential regulation by the
19
20 autonomic nervous system in chronic fatigue syndrome. *Journal of Internal Medicine*, 267(4),
21
22 394-401.
23
24 (14) Newton, J. L., Pairman, J., Hallsworth, K., Moore, S., Plotz, T., & Trenell, M. I. (2011). Physical
25
26 activity intensity but not sedentary activity is reduced in chronic fatigue syndrome and is
27
28 associated with autonomic regulation. *International Journal of Medicine*, 104(8), 681-687.
29
30 (15) Candy, J. V., Meyer, A. W., Poggio, A. J., & Guidry, B. L. (2004). Time-reversal processing for an
31
32 acoustic communications experiment in a highly reverberant environment. *The Journal of*
33
34 *the Acoustical Society of America*, 115(4), 1621-1631.
35
36 (16) Moss-Morris R, Spence M, Hou R (2010). The pathway from glandular fever to chronic fatigue
37
38 syndrome: can the cognitive behavioural model provide the map? *Psychol Med*, 41(5), 1099-
39
40 101.
41
42 (17) Moss-Morris, R., Deary, V. & Castell, B. (2012). Chronic Fatigue Syndrome. Chapter 25 In:
43
44 Barnes, M. P., & Good, D. C. (Eds.). (2012). *Neurological Rehabilitation: Handbook of Clinical*
45
46 *Neurology* (Series Editors: Aminoff, Boller and Swaab) (Vol. 110). Elsevier.
47
48
49 (18) Komaroff, A. L., & Buchwald, D. (1991). Symptoms and signs of chronic fatigue syndrome.
50
51 *Reviews of infectious diseases*, 13 Suppl 1, S8-11.
52
53
54
55
56
57
58
59
60

- 1
2
3 (19) Manu, P., Lane, T. J., & Matthews, D. A. (1988). The frequency of the chronic fatigue syndrome
4
5 in patients with symptoms of persistent fatigue. *Annals of Internal Medicine*, 109(7), 554-
6
7 556.
8
9
10 (20) Gotts, Z. M. Unpublished PhD Thesis
11
12 (21) Nisenbaum, R., Jones, J. F., Unger, E. R., Reyes, M., & Reeves, W. C. (2003). A population-based
13
14 study of the clinical course of chronic fatigue syndrome. *Health and Quality of Life*
15
16 *Outcomes*, 1, 49.
17
18 (22) Turner, T. H., Drummond, S., Salamat, J. S., & Brown, G. G. (2007). Effects of 42 hr of total sleep
19
20 deprivation on component processes of verbal working memory. *Neuropsychology*, 21(6),
21
22 787.
23
24 (23) Van Cauter, E., Leproult, R., & Plat, L. (2000). Age-related changes in slow wave sleep and REM
25
26 sleep and relationship with growth hormone and cortisol levels in healthy men. *JAMA: the*
27
28 *journal of the American Medical Association*, 284(7), 861-868.
29
30
31 (24) Stickgold, R. (2005). Sleep-dependent memory consolidation. *Nature*, 437(7063), 1272-1278.
32
33 (25) Roberts, A. D. L., Wessely, S., Chalder, T., Papadopoulos, A., & Cleare, A. J. (2004). Salivary
34
35 cortisol response to awakening in chronic fatigue syndrome. *British Journal of Psychiatry*,
36
37 184, 136-141.
38
39 (26) Buchwald, D., Pascualy, R., Bombardier, C., & Kith, P. (1994). Sleep disorders in patients with
40
41 chronic fatigue. *Clinical infectious diseases : an official publication of the Infectious Diseases*
42
43 *Society of America*, 18(1), S68-72.
44
45 (27) Krupp, L. B., Jandorf, L., Coyle, P. K., & Mendelson, W. B. (1993). Sleep disturbance in chronic
46
47 fatigue syndrome. *Journal of Psychosomatic Research*, 37(4), 325-331.
48
49 (28) Manu, P., Lane, T. J., Matthews, D. A., Castriotta, R. J., Watson, R. K., & Abeles, M. (1994). Alpha-
50
51 delta sleep in patients with a chief complaint of chronic fatigue. *Southern medical journal*,
52
53 87(4), 465-470.
54
55
56
57
58
59
60

- 1
2
3 (29) Whelton, C. L., Salit, I., & Moldofsky, H. (1992). Sleep, epstein-barr virus infection,
4
5 musculoskeletal pain, and depressive symptoms in chronic fatigue syndrome. *J Rheumatol*,
6
7 19(6), 939-943.
8
- 9 (30) Creti, L., Libman, E., Baltzan, M., Rizzo, D., Bailes, S., & Fichten, C. S. (2010). Impaired sleep in
10
11 chronic fatigue syndrome how is it best measured? *Journal of Health Psychology*, 15(4), 596-
12
13 607.
14
- 15 (31) Decker, M. J., Tabassum, H., Lin, J. M. S., & Reeves, W. C. (2009). Electroencephalographic
16
17 correlates of chronic fatigue syndrome. *Behavioral and Brain Functions*, 5.
18
- 19 (32) Fossey, M., Libman, E., Bailes, S., et al. (2004). Sleep quality and psychological adjustment in
20
21 chronic fatigue syndrome. *Journal of Behavioral Medicine*, 27(6), 581-605.
22
23
- 24 (33) Kishi, A., Natelson, B. H., Togo, F., Struzik, Z. R., Rapoport, D. M., & Yamamoto, Y. (2010). Sleep
25
26 stage transitions in chronic fatigue syndrome patients with or without fibromyalgia. *Conf*
27
28 *Proc IEEE Eng Med Biol Soc*, 1, 5391-5394.
29
- 30 (34) Watson, N. F., Jacobsen, C., Goldberg, J., Kapur, V., & Buchwald, D. (2004). Subjective and
31
32 objective sleepiness in monozygotic twins discordant for chronic fatigue syndrome. *Sleep*,
33
34 27(5), 973-977.
35
- 36 (35) Armitage, R., Landis, C., Hoffmann, R., et al. (2007). The impact of a 4-hour sleep delay on slow
37
38 wave activity in twins discordant for chronic fatigue syndrome. *Sleep*, 30(5), 657-662.
39
- 40 (36) Ball, N., Buchwald, D. S., Schmidt, D., Goldberg, J., Ashton, S., & Armitage, R. (2004).
41
42 Monozygotic twins discordant for chronic fatigue syndrome - objective measures of sleep.
43
44 *Journal of Psychosomatic Research*, 56(2), 207-212.
45
46
- 47 (37) Fischler, B., LeBon, O., Hoffmann, G., Cluydts, R., Kaufman, L., & DeMeirleir, K. (1997). Sleep
48
49 anomalies in the chronic fatigue syndrome - a comorbidity study. *Neuropsychobiology*, 35(3),
50
51 115-122.
52
53
54
55
56
57
58
59
60

- 1
2
3 (38) Majer, M., Jones, J. F., Unger, E. R., et al. (2007). Perception versus polysomnographic
4
5 assessment of sleep in cfs and non-fatigued control subjects: Results from a population-
6
7 based study. *BMC Neurology*, 7.
8
9 (39) Reeves, W. C., Heim, C., Maloney, E. M., et al. (2006). Sleep characteristics of persons with
10
11 chronic fatigue syndrome and non-fatigued controls: Results from a population-based study.
12
13 *BMC Neurology*, 6.
14
15 (40) Stores, G., Fry, A., & Crawford, C. (1998). Sleep abnormalities demonstrated by home
16
17 polysomnography in teenagers with chronic fatigue syndrome. *Journal of Psychosomatic*
18
19 *Research*, 45(1), 85-91.
20
21 (41) Van Hoof, E., De Becker, P., Lapp, C., Cluydts, R., & De Meirleir, K. (2007). Defining the
22
23 occurrence and influence of alpha-delta sleep in chronic fatigue syndrome. *American Journal*
24
25 *of the Medical Sciences*, 333(2), 78-84.
26
27 (42) Watson, N. F., Kapur, V., Arguelles, et al. (2003). Comparison of subjective and objective
28
29 measures of insomnia in monozygotic twins discordant for chronic fatigue syndrome. *Sleep*,
30
31 26(3), 324-328.
32
33 (43) Le Bon, O., Minner, P., Van Moorsel, C., et al. (2003). First-night effect in the chronic fatigue
34
35 syndrome. *Psychiatry Research*, 120(2), 191-199.
36
37 (44) Le Bon, O., Neu, D., Valente, F., & Linkowski, P. (2007). Paradoxical nrems distribution in "pure"
38
39 chronic fatigue patients: A comparison with sleep apnea-hypopnea patients and healthy
40
41 control subjects. *Journal of Chronic Fatigue Syndrome*, 14(2), 45-60.
42
43 (45) Morriss, R., Sharpe, M., Sharpley, A. L., Cowen, P. J., Hawton, K., & Morris, J. (1993).
44
45 Abnormalities of sleep in patients with the chronic fatigue syndrome. *British Medical*
46
47 *Journal*, 306(6886), 1161-1164.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (46) Sharpley, A., Clements, A., Hawton, K., & Sharpe, M. (1997). Do patients with "pure" chronic
4
5 fatigue syndrome (neurasthenia) have abnormal sleep? *Psychosomatic Medicine*, 59(6), 592-
6
7 596.
8
9
10 (47) Togo, F., Natelson, B. H., Cherniack, N. S., FitzGibbons, J., Garcon, C., & Rapoport, D. M. (2008).
11
12 Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting
13
14 fibromyalgia. *Arthritis Research & Therapy*, 10(3).
15
16 (48) Guilleminault, C., Poyares, D., da Rosa, A., Kirisoglu, C., Almeida, T., & Lopes, M. C. (2006).
17
18 Chronic fatigue, unrefreshing sleep and nocturnal polysomnography. *Sleep Medicine*, 7(6),
19
20 513-520.
21
22 (49) Rahman, K. B., A. Galbraith, S. Lloyd, A. & Vollmer-Conna, U. (2011). Sleep-wake behavior in
23
24 chronic fatigue syndrome. *Sleep*, 34(5), 671-678.
25
26 (50) American Academy of Sleep Medicine. (2007) *The AASM manual for the scoring of sleep and*
27
28 *associated events : rules, terminology and technical specifications*. Washington DC. Author.
29
30 (51) Carskadon, M. & Dement, W.C. (2011). Normal human sleep: An overview. Chapter 2 In Kryger,
31
32 M.H., Roth, T. & Dement, W.C. *Principles and Practice of Sleep Medicine* (5th Edition).
33
34 Elsevier: Missouri.
35
36 (52) Edinger, J. D., Bonnet, M. H., Bootzin, R. R., et al. (2004). Derivation of research diagnostic
37
38 criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. *Sleep*,
39
40 27(8), 1567-1596.
41
42 (53) Dündar, Y., Dodd, S., Strobl, J., Boland, A., Dickson, R., & Walley, T. (2004). Comparative efficacy
43
44 of newer hypnotic drugs for the short-term management of insomnia: a systematic review
45
46 and meta-analysis. *Human Psychopharmacology: Clinical and Experimental*, 19(5), 305-322.
47
48 (54) Brandenberger, G., Buchheit, M., Ehrhart, J., Simon, C., & Piquard, F. (2005). Is slow wave sleep
49
50 an appropriate recording condition for heart rate variability analysis? *Autonomic*
51
52 *Neuroscience*, 121(1), 81-86.
53
54
55
56
57
58
59
60

- 1
2
3 (55) Dauvilliers, Y. (2006). Differential diagnosis in hypersomnia. *Current neurology and neuroscience*
4 *reports*, 6(2), 156-162.
5
6
7 (56) Ohayon, M. M. (2002). Epidemiology of insomnia: what we know and what we still need to
8 learn. *Sleep medicine reviews*, 6(2), 97-111.
9
10
11 (57) Buysse, D. J., Cheng, Y., Germain, A., et al. (2010). Night-to-night sleep variability in older adults
12 with and without chronic insomnia. *Sleep medicine*, 11(1), 56.
13
14 (58) Perlis, M.L., Swinkles, C.M., Gherman, P.R., Pigeon, W.R., Matteson-Rusby, S.E., Jungvist, C. R.
15 (2009). The incidence and temporal patterning of insomnia: a pilot study. *Journal of Sleep*
16 *Research*, 19(1), 31-35.
17
18 (59) Vallieres, A., Ivers, H., Beaulieu-Bonneau, S. & Morin, C.M. (2011). Predictability of Sleep in
19 Patients with Insomnia. *Sleep*, 34(5), 609-617.
20
21 (60) Wohlgemuth, W.K., Edinger, J.D., Fins, A.I. & Sullivan, R.J. (1999). How many nights are enough?
22 The short-term stability of sleep parameters in elderly insomniacs and normal sleepers.
23 *Psychophysiology*, 36(2), 233-244.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*


	Item No	Recommendation
X Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
X Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
X Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
X Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

X Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
X Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Figure 1: Study Overview



Study Overview
254x190mm (72 x 72 DPI)



Are there sleep-specific phenotypes in patients with Chronic Fatigue Syndrome? A cross-sectional polysomnography analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002999.R1
Article Type:	Research
Date Submitted by the Author:	24-Apr-2013
Complete List of Authors:	Gotts, Zoe; Northumbria University, Northumbria Centre for Sleep Research Deary, Vincent; Northumbria University, Psychology Newton, Julia; Newcastle University, Institute for Ageing and Health van der Dussen, Donna; VermoeidheidCentrum Nederland bv, Fatigue Service de Roy, Pierre; VermoeidheidCentrum Nederland bv, Fatigue Service Ellis, Jason; University of Northumbria, Northumbria Centre for Sleep Research
Primary Subject Heading:	Patient-centred medicine
Secondary Subject Heading:	Patient-centred medicine, General practice / Family practice, Evidence based practice
Keywords:	INTERNAL MEDICINE, SLEEP MEDICINE, STATISTICS & RESEARCH METHODS, MENTAL HEALTH

SCHOLARONE™
Manuscripts

1
2
3 Are there sleep-specific phenotypes in patients with Chronic Fatigue Syndrome? A cross-sectional
4
5 Polysomnography analysis
6
7
8

9
10 Zoe M. Gotts MSc^a, Vincent Deary PhD^a, Julia Newton MD^b, Donna van der Dussen MD^c, Pierre de
11
12 Roy MD^c, Jason G. Ellis PhD^{a*}
13

14
15
16 * Corresponding Author

17 Dr Jason G Ellis

18 Northumbria Centre for Sleep Research

19 School of Life Sciences

20 Northumbria University

21 138 Northumberland Building

22 Newcastle-upon-Tyne

23 NE1 8ST

24 Jason.ellis@northumbria.ac.uk

25 +44(0)1912273081
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- a) Northumbria Centre for Sleep Research, Northumbria University, Newcastle, UK
b) Institute for Ageing and Health, Newcastle University, Newcastle, UK
c) VermoeidheidCentrum Nederland bv, Lelystad, Netherlands

ABSTRACT

Objectives: Despite sleep disturbances being a central complaint in patients with Chronic Fatigue Syndrome (CFS), evidence of objective sleep abnormalities, from over 30 studies, is inconsistent. The present study aimed to identify whether sleep-specific phenotypes exist in CFS and explore objective characteristics that could differentiate phenotypes, whilst also being relevant to routine clinical practice.

Design: A cross-sectional, single-site, study.

Setting: A fatigue clinic in the Netherlands

Participants: A consecutive series of 343 patients meeting criteria for CFS, according to the Fukuda definition.

Measures: Patients underwent a single night of polysomnography (all-night recording of Electroencephalography, Electromyography, Electrooculography, Electrocardiogram and Respiration) that were hand-scored by a researcher blind to diagnosis and patient history.

Results: Of the 343 patients, 104 (30.3%) were identified with a Primary Sleep Disorder explaining their diagnosis. A hierarchical cluster analysis on the remaining 239 patients resulted in four sleep phenotypes identified at saturation. Of the 239 patients, 89.1% met quantitative criteria for at least one objective sleep problem. A one-way ANOVA confirmed distinct sleep profiles for each sleep phenotype. Relatively longer sleep onset latencies, longer Rapid Eye Movement (REM) latencies, and smaller percentages of both Stage 2 and REM characterized the first phenotype. The second phenotype was characterised by more frequent arousals per hour. The third phenotype was characterised by a longer Total Sleep Time, shorter REM Latencies, and a higher percentage of REM and low percentage of wake time. The final phenotype had the shortest Total Sleep Time and the highest percentage of wake time and wake after sleep onset.

1
2
3 Conclusions: The results highlight the need to routinely screen for Primary Sleep Disorders in clinical
4 practice and tailor sleep interventions, based on phenotype, to patients presenting with CFS. The
5 results are discussed in terms of matching patients' self-reported sleep to these phenotypes in
6 clinical practice.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Focus

- Despite 85-90% of patients with CFS reporting unrefreshing sleep, previous research has been unable to reliably identify specific irregularities in objective sleep
- To explore the possibility that sleep problems in this population are not homogeneous and that several sleep-specific phenotypes exist in this population which are amenable to different treatment approaches

Key Messages

- Over 30% of individuals with CFS, met diagnostic criteria for Sleep Apnoea or Periodic Limb Movement Disorder that could explain their current diagnosis.
- The sleep in those with CFS, without Sleep Apnoea or Periodic Limb Movement Disorder, centred around four specific sleep-disturbed phenotypes with 89.1% demonstrating quantitative criteria for insomnia or hypersomnolence.
- Each sleep-phenotype in CFS comprised objective characteristics that could be assessed and differentiated using patient's self-reports in primary care.

Strengths and Limitations:

- This is the first study to suggest, and identify, specific sleep-phenotypes in a large sample of patients with CFS.
- The objective findings can be easily translated and applied in routine primary care.
- A limitation is the use of a single-night of Polysomnography.

INTRODUCTION

Chronic Fatigue Syndrome (CFS), as defined by the international consensus definition¹ is a condition characterised by profound fatigue, of definite onset, which has persisted for at least 6 months, and causes substantial disruption to the individual's daily functioning. In addition to fatigue, at least four other key symptoms are required to fulfil diagnostic criteria, including muscle and joint pain, headache, cognitive dysfunction and unrefreshing sleep. Thus defined, CFS affects between 0.23-2.6% of the adult population²⁻⁴. There are several theories as to the pathogenesis of CFS. However it is likely the development and maintenance of CFS is multifactorial. Predisposing factors include a general propensity to both emotional and physical distress, history of abuse, being more than usually physically active, and being perfectionist⁵⁻⁸. Precipitating events include viruses such as glandular fever and major life events⁹⁻¹⁰. Several factors appear to be involved in the maintenance of symptoms. Physiologically, evidence suggests dysregulation of the hypothalamic pituitary adrenal (HPA) axis, increased cytokine production and HPA responsiveness to cytokines¹¹⁻¹², hypersensitivity in the Central Nervous System (i.e. central sensitisation)¹³⁻¹⁴, and autonomic dysfunction¹⁵⁻¹⁶. Two studies also highlight the importance of illness beliefs and behaviours¹⁷⁻¹⁸. Individuals who adopt all or nothing coping styles in response to symptoms (i.e. push on through until they crash out) and attribute broad ranges of everyday symptoms to their illness are more likely to develop CFS post-virally. In sum, research suggests in CFS multiple processes in distinct domains, such as physiology, illness beliefs, inconsistent activity, sleep disturbance, medical uncertainty, and lack of guidance, can interact to maintain or exacerbate symptoms¹⁹.

As mentioned above, unrefreshing sleep is one key diagnostic characteristic of CFS¹. It is also one of the most common symptom complaints²⁰⁻²¹ with 87-95% of patients reporting sleep difficulties²² that do not improve over the course of the illness²³. Where the purpose of sleep is subject to intense debate, its importance to human health and well-being is undeniable. Examinations of individuals

1
2
3 deprived or restricted of sleep consistently demonstrate deteriorations in mood, cognition, and
4 performance²⁴. The purpose of each different sleep stage is also unclear although it is generally
5 agreed that the lighter stages of sleep (stage 1 sleep and stage 2 sleep) afford transitions between
6 wakefulness and sleep and then between slow wave sleep (SWS) and Rapid Eye Movement sleep
7 (REM). SWS and REM are believed to confer recuperative, restorative, and learning properties for
8 the individual (e.g. the secretion of growth hormone, consolidation of memory)²⁵⁻²⁶. Therefore, the
9 proportion of each sleep stage and timing of entry into each sleep stage, SWS and REM in particular,
10 are important for the long-term maintenance of human physical and mental health.
11
12
13
14
15
16
17
18
19

20
21
22 Symptoms such as unrefreshing sleep may not only be markers of CFS but may also serve to
23 maintain it. For instance there may be reciprocal links between sleep quality, sleep-wake regulation
24 and fatigue. There is evidence of this, for instance, studies have shown that adopting activity and
25 sleep management strategies improves HPA axis functioning as measured by cortisol levels²⁷. This
26 suggests further investigation of sleep disturbance of CFS is of more than academic importance but
27 may highlight new avenues for intervention. From a clinical perspective it is also important to study
28 sleep more thoroughly in CFS as it may highlight some areas of diagnostic ambiguity. For instance
29 previous studies have shown sleep disorders (notably obstructive sleep apnoea) are occasionally
30 identified during PSG assessments with CFS patient cohorts²⁸⁻³¹.
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Although over 30 Polysomnographic (PSG) studies on individuals with CFS exist, conclusive
45 statements about the type of sleep abnormalities in this population are difficult. Few studies report
46 a full characterisation of both sleep continuity (the timing, efficiency, and amount of sleep obtained)
47 and sleep architecture (amount of each sleep or wake stage and the timing of transitions to each
48 sleep stage), with some studies providing no PSG data at all^{28, 32-36}. Moreover, reporting practices
49 differ widely making interpretation and comparisons difficult (e.g. studies report the percentage of
50
51
52
53
54
55
56
57
58
59
60

1
2
3 each sleep and wake stage as an index of Sleep Period Time, Total Sleep Time or even Time in Bed³⁰⁻
4
5 ^{31; 37-44} whilst others report minutes of each stage⁴⁵⁻⁴⁹. What can be concluded from previous PSG
6
7 studies is in each study deviations from 'normal sleep' exist but there is no consistent pattern. For
8
9 example, where two studies⁴⁵⁻⁴⁶ report poor sleep efficiencies and 'normal range' REM latencies,
10
11 others^{37-38,46} found 'normal range' sleep efficiencies and short REM latencies and others still report a
12
13 normal sleep efficiency and a long REM latency⁴² or poor sleep efficiency and long REM latencies⁴⁹.
14
15 Moreover, the picture remains unclear after controlling for the severity of patients' self-reported
16
17 sleep complaints⁵⁰⁻⁵¹. Although differences in protocol, definitional criteria, and reporting criteria
18
19 may, to some extent, explain these differences, an alternative explanation is sleep difficulties in
20
21 individuals with CFS are not homogenous and various sleep phenotypes exist in this population.
22
23
24
25
26
27

28 To clarify the specific characterisation of sleep in CFS, the current study examined polysomnographic
29
30 data for a single night of sleep in a large group of CFS patients, to determine whether specific sleep
31
32 disturbances exist in this group, and if so, are these consistent across all patients.
33
34
35
36
37

38 METHOD

39
40
41 A cross-sectional, single-site, observational study was undertaken on a consecutive series of 343
42
43 patients (Mean age 37.21±12.42 years; 72 males 271 females) referred for a single-night
44
45 polysomnographic (PSG) study at a fatigue clinic in the Netherlands. The referral criteria for PSG
46
47 investigation were that the patient, a) met diagnostic criteria for CFS according the Fukuda definition
48
49 (1), b) they were drug-free for at least two-weeks prior to the overnight study, and c) their
50
51 symptoms could not be explained by a physical or psychological illness (e.g. anxiety or depression).
52
53
54 Patients gave informed consent to take part in the study and then were interviewed and medically
55
56
57
58
59
60

1
2
3 screened for the referral criteria by a registered physician and a registered psychiatrist. The Ethics
4
5 Committee for the School of Life Sciences at Northumbria University had approved the study.
6
7
8
9

10
11 Patients arrived at the clinic two hours before normal bedtime for electrode placement and bio-
12 calibration. The PSG montage comprised a standard 10/20 (i.e. F₄-M₁, C₄-M₁, O₂-M₁ and C_z with
13 backups at F₃-M₂, C₃-M₂, O₁-M₂ and F_{p2}). Additional channels were used for EOG (E₁ and E₂
14 referenced to M₂), EMG (chin and anterior tibialis placements), ECG, and airflow, effort, body
15 position, and oximetry (via pulse oximeter). Filter settings were set to American Academy of Sleep
16 Medicine⁵² guidelines (e.g. low 0.3Hz / high 35Hz for EEG and EOG) with a sampling rate of 500Hz.
17 Impedances were maintained below 5KΩ. Participants slept in the laboratory overnight and were
18 allowed to retire to bed when they wished and left to naturally wake in the morning. Scoring was
19 conducted manually by a registered BRPT certified technician at 30-second epochs, according to
20 AASM guidelines. The scorer was blind to the aims of the study. The mean recording period was just
21 over 8 hours (508.5 ± 63.11 minutes). Descriptions of all sleep variables are detailed in Table 1.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Table 1: Description of sleep variables

Total Sleep Time (minutes)	Amount of time asleep
Sleep Onset Latency (minutes)	Length of time from lights out to first episode of stage 2 sleep
Wake After Sleep Onset (minutes)	Number of minutes of recorded wake following first episode of stage 2 sleep
Number of Awakenings (over TSP)	Number of wake bouts following first episode of stage 2 sleep
Number of Arousals	Number of arousals over the entire sleep period
Sleep Efficiency	Percentage of overall time spent in bed asleep
REM Latency	Length of time to first REM stage
AHI Index	Number of apnoea or hypopnea events per hour of sleep
% N1 (of TST)	Percentage of recorded stage 1 sleep over the total time asleep
% N2 (of TST)	Percentage of recorded stage 2 sleep over the total time asleep
% N3 (of TST)	Percentage of recorded slow wave sleep over the total time asleep
% REM (of TST)	Percentage of recorded Rapid Eye Movement sleep over the total time asleep
% WAKE (of TSP)	Percentage of recorded wake over the whole sleep period (from lights out to lights on)

52
53
54
55
56
57 Analytic Strategy

1
2
3 A hierarchical Cluster Analysis was used to determine the number of phenotypes within the present
4 sample after excluding those with Sleep Apnoea or Periodic Limb Movement Disorder. Cluster
5 analysis is a data reduction technique that examines patterns amongst a set of variables to form
6 homogenous groups. The Euclidean squared distance measure of similarity method was chosen for
7 the cluster analysis as it uses the progressive distance between variables to form the groups and
8 does not rely upon standardised data. As cluster analysis can be affected by multicollinearity, a
9 correlation matrix was used to exclude variables that were highly correlated with one another. A
10 One-Way Analysis Of Variance (ANOVA) was used to examine which of the sleep variables
11 differentiated the phenotypes.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 RESULTS

27
28
29 An initial examination of the Apnoea Hypopnoea Index (AHI) and Periodic Limb Movements (PLM's)
30 indices indicated that 104 (43 males and 61 females) of the original 343 referrals (30.3%) met AASM
31 criteria for either sleep apnoea (AHI ≥ 15 ; n = 101) or a periodic limb movement disorder (PLMs ≥ 5 ;
32 n =17) (14 participants met criteria for both disorders). The overall sleep profile of the remaining 239
33 patients (Mean Age 34.4 \pm 11.84; 210 females and 29 males) was highly variable indicating the
34 presence of phenotypes (Figure 1).
35
36
37
38
39
40
41
42
43
44
45

46 Insert Figure 1 Here
47
48
49
50
51

52 A hierarchical cluster analysis, using Ward's method, was undertaken to determine the number of
53 groups (clusters) within the remaining 239 patients. Prior to the cluster analysis a correlation matrix
54 was examined to avoid multicollinearity influencing the cluster model. On this basis four variables
55
56
57
58
59
60

1
2
3 were excluded (Height, Weight, Sleep Efficiency, and number of Spontaneous Arousals per hour) for
4
5 having correlation coefficients with one or more variables above $r = .8$. The final grouping variables
6
7 included in the cluster analysis were; age, sex, BMI, AHI's, PLM index, Number of Awakenings,
8
9 Number of Arousals per hour, Total Sleep Time (TST), Sleep Latency (SL), Wake After Sleep Onset
10
11 (WASO), percentage of %N1 (stage 1 sleep) of TST, %N2 (stage 2 sleep) of TST, %N3 (SWS) of TST,
12
13 %WAKE of TST, %REM of TST, and REM Latency (REML). The Euclidean squared distance measure of
14
15 similarity was used to group patients according to the included variables.
16
17
18
19
20

21
22 There were 6 clustering iterations overall (going from 8 clusters to 2). The fourth iteration was
23
24 chosen as saturation point as it was where the agglomeration schedule and dendrogram had the
25
26 highest reduction in the number of groupings (from six groups to four groups = reduction of 33%)
27
28 whilst retaining at least 5% of the total sample size in each group (i.e. $n \geq 11$). This latter rule was
29
30 chosen to afford sufficient power for inferential data analysis to occur.
31
32
33
34
35

36 A one-way ANOVA was undertaken on the four groups to determine which sleep variables
37
38 significantly differentiated the groups. There were no overall differences between the groups on age
39
40 ($p = .12$) or BMI ($p = .48$). On inspection of the sex frequencies in each group, there was a higher ratio
41
42 of males to females in the first group compared to the other three groups. However, as two groups
43
44 contained less than 5 males this could not be tested statistically. In relation to the polysomnography
45
46 variables there were no group differences in the number of arousals per hour or AHI index scores
47
48 (PLMs were not included as less than 10% of the total sample had a PLM index), but significant
49
50 differences were observed on all the other sleep variables (Table 2).
51
52
53
54
55
56
57
58
59
60

Table 2: Characteristics of sample of individuals with CFS

Grouped Variable Clusters	Group 1 (N = 14)	Group 2 (N = 55)	Group 3 (N = 146)	Group 4 (N = 24)	F	p
Demographics						
Age	35.79 (12.39)	37.29 (12.72)	32.99 (10.82)	35.54 (14.49)	1.95	n.s.
Sex	5 Males (35.71%)	10 Males (17.65%)	14 Males (9.59%)	1 Male (4.17%)	**	**
BMI	24.86 (5.68)	23.85 (4.63)	23.41 (4.03)	22.81 (3.86)	0.82	n.s.
Sleep Variables						
Total Sleep Time (minutes)	270.95 (41.85)ab	387.03 (46.1)acd	473.21 (45.82)bce	264.15 (74.43)de	188.07	p<.001
Sleep Onset Latency (minutes)	107.79 (42.09)abc	30.97 (29.13)ad	19.17 (14.71)bd	28.94 (27.54)c	67.26	p<.001
Wake After Sleep Onset (minutes)	75.79 (39.35)ab	82.12 (45.25)cd	35.45 (25.39)ace	180.2 (58.48)bde	119.74	p<.001
Number of Awakenings (over TSP)	15.21 (8.06)	14.75 (11.62)ab	9.54 (5.85)a	16.96 (9.26)b	10.52	p<.001
Number of Arousals	3.57 (9.21)	10.91 (23.01)	6.2 (15.26)	1.38 (4.13)	2.24	n.s.
REM Latency	173.22 (55.03)abc	57.71 (34.31)ad	47.01 (28.22)be	84.46 (48.21)cde	63	p<.001
AHI Index	3.43 (3.46)	4.58 (4.39)	4.73 (4.04)	3.54 (4.19)	0.92	n.s.
% N1 (of TST)	21.84 (13.36)a	14.35 (9.14)b	12.55 (7.37)ac	24.22 (14.82)bc	14.15	p<.001
% N2 (of TST)	27.57 (13.15)ab	38.82 (12.36)a	38.44 (12.14)b	36.95 (13.66)	3.46	p<.02
% N3 (of TST)	44.46 (20.45)abc	31.07 (11.05)a	31.78 (12.41)b	29.28 (16.42)c	4.64	p<.004
% REM (of TST)	6.11 (4.58)abc	15.16 (5.47)ad	17.19 (5.57)be	9.65 (6.35)cde	26.46	p<.001
% WAKE (of TSP)	60.32 (21.09)abc	25.75 (11.61)ade	11.03 (6.16)bdf	75.26 (22.92)cef	271.62	p<.001

Notes

Letters sharing the same subscript are significantly different

**Statistical tests of between-group sex differences could not be performed due to the small number of men in each group

First Phenotype

The first phenotype comprised 14 patients with the longest Sleep Onset and REM Latencies and the highest percentage of SWS. Moreover, this group had the lowest percentages of both Stage 2 sleep and REM sleep. Statistically; this phenotype differed from the other three groups in terms of longer Sleep Onset and REM latencies, and a lower percentage of REM.

Second Phenotype

The second phenotype comprised 55 patients with the highest percentage of Stage 2 sleep and the highest number of arousals per hour although neither of these variables statistically separated them from all three other phenotypes.

Third Phenotype

The third phenotype comprised 146 patients with the highest Total Sleep Time and percentage of REM. Additionally, this group demonstrated the shortest Sleep Onset and REM Latencies, lowest wake after sleep onset and percentages of wake time and Stage 1 sleep, and the lowest number of

1
2
3 awakenings. Statistically, Total Sleep Time, percentage wake, and wake after sleep onset
4
5 differentiated this phenotype from each of the others.
6
7

8 *Fourth Phenotype*

9

10 The fourth phenotype comprised 24 patients who demonstrated the highest wake after sleep onset,
11
12 percentages of wake and Stage 1 sleep, and the highest number of awakenings. This group were also
13
14 the lowest in terms of Total Sleep Time, number of arousals per hour, and percentage of SWS.
15
16 Statistically, only wake after sleep onset and percentage of wake differentiated this group from each
17
18 of the others.
19
20
21
22
23
24

25 DISCUSSION

26

27
28 The aim of the study was to determine whether specific sleep phenotypes existed in patients with
29
30 CFS. A large consecutive series of patients, meeting criteria for CFS, underwent a single night of
31
32 polysomnography to determine the presence or absence of distinct sleep phenotypes. The first
33
34 finding, over 30% of individuals meeting diagnostic criteria for CFS also demonstrated a Primary
35
36 Sleep Disorder (sleep apnoea or PLMD) is important and underscores the need to assess for Primary
37
38 Sleep Disorders (PSDs) in CFS populations. As recommended treatment strategies for some PSDs
39
40 differ considerably from those for CFS (e.g. Continuous Positive Airway Pressure for apnoea vs. sleep
41
42 management strategies in CFS) it is important to direct the individual to, or adjunct, appropriate care
43
44 pathways as soon as possible. This finding also questions the ability to differentiate fatigue
45
46 associated with sleep apnoea or PLMD from that associated with CFS. Here family members and/or
47
48 carers may be helpful for diagnosis sensitivity as they are likely to be aware of nocturnal breathing
49
50 disturbances (i.e. heavy snoring, gasping or pauses in breathing).
51
52
53
54
55
56
57
58
59
60

1
2
3 The overall PSG results (after excluding sleep apnoea and PLMD) confirm objective sleep difficulties
4
5 in patients with CFS. When comparing percentages of each sleep stage in 'normal' adult sleepers (i.e.
6
7 $\leq 5\%$ wake, between 2-5% stage 1, between 45-55% stage 2, between 13-23% SWS, and between 20-
8
9 25% REM⁵³) to the present sample this group fall outside the range on all these variables. The
10
11 present sample are spending more time awake and in the lighter stages of sleep (stage 1 and 2
12
13 sleep), and less time in deeper sleep stages of sleep (i.e. stage 2 sleep and SWS) and in REM. Further,
14
15 using the quantitative benchmarks of sleep disturbance outlined by Edinger⁵⁴ it can be seen that
16
17 where sleep efficiency and sleep latencies appear to be on the cusp of 'normal' sleep in the present
18
19 sample (85% sleep efficiency is considered normal and a sleep latency of ≥ 30 denotes a sleep
20
21 problem), wake after sleep onset appears to be almost twice as long as is considered problematic
22
23 (≥ 30 minutes tends to denote a sleep problem). Together, these findings indicate that sleep is an
24
25 objectively verifiable problem for patients with CFS that should be addressed clinically.
26
27
28
29
30
31

32
33 The cluster analysis identified, at saturation, four sleep phenotypes. The dendrogram identified two
34
35 groups partially related (i.e. groups one and four) and two that were largely independent (i.e. groups
36
37 two and three). This configuration was confirmed by the ANOVA showing statistically significant
38
39 differences in sleep continuity and architecture variables between the groups. That said, where
40
41 statistical significance and relative characterisation (e.g. highest in variable WX and Y and lowest in
42
43 variable Z) are important in understanding between-group differences the more salient question is
44
45 whether these four groups are clinically relevant in terms of specific sleep treatments in patients
46
47 with CFS. The use of different pharmacological agents (benzodiazepines, z-hypnotics, or stimulants)
48
49 or therapeutic interventions (i.e. Cognitive Behavioural Therapy for Insomnia or behavioural
50
51 modification strategies) has been shown to have differential effects on specific aspects of sleep
52
53 continuity and architecture. For example, zolpidem appears to have a better impact on the number
54
55 of awakenings and perceived quality of sleep compared to nitrazepam, and lormetazepam appears
56
57
58
59
60

better in reducing sleep latencies than zopiclone⁵⁵. As such tailoring treatment options to the presenting sleep problems in this population is likely to be more effective (Table 3).

Table 3: Characteristics (statistical and phenomenological) of patients with CFS

Sleep Phenotype	Central Differential Features	Associated Diagnostic Features	How this may present subjectively
1	Long Sleep Onset Latency Long REM Latency High amounts of Slow Wave Sleep Low amounts of REM	Low amounts of Stage 2 Sleep	Problems in getting off to sleep but when asleep few awakenings. The Sleep that is obtained is of normal quality.
2		High number of arousals per hour High amounts of Stage 2 Sleep	No difficulties in getting off to sleep and few awakenings but feelings or evidence of a 'restless' nights sleep
3	High Total Sleep Time Low amounts of time awake during the night Low number of wake periods during the night	High amounts of REM Sleep Short Sleep Onset Latency Low number of Awakenings Short REM Latencies Low amounts of Stage 1 Sleep	No difficulties in getting off to sleep and few awakenings but feelings of being unrefreshed on waking despite a significant amount of time in bed asleep.
4	Highest number of wake periods during the night Highest amounts of time awake during the night	Low Total Sleep Time Low number of arousals per hour during the night Low amounts of Slow Wave Sleep	Short sleep duration and although no difficulties getting off to sleep lots of awakenings for significant periods of time. Also increased feelings of daytime sleepiness.

Another, albeit related, consideration is the presence within the final sample of PSDs for which PSG is either not routinely recommended or where stand-alone it is insufficient for a definitive diagnosis⁵². Most relevant to the present sample are insomnia disorder and hypersomnolence disorders. Interestingly, groups one and four appear to be characterised by insomnia-like symptoms (i.e. difficulties initiating sleep or maintaining sleep) whereas groups two and three appear to share overlapping characteristics with disorders characterised by poor sleep quality (Table 2). In relation to group three there is some overlap with hypersomnolence disorders (the term hypersomnolence will replace hypersomnia under the DSM-5) as 14 patients (9.59%) slept for nine hours or longer and eight patients (5.48%) demonstrated the main polysomnographically defined symptom of narcolepsy (i.e. a REM Latency of less than 15 minutes). For group two there is no obvious overlap with a

1
2
3 specific DSM-5-defined sleep disorder although as Stage 2 sleep has been associated with hormonal
4 and autonomic regulation⁵⁶ increased amounts are likely to relate to both higher levels of autonomic
5 and cortical arousal inhibiting deep sleep. As such, a PSG study with adjunct sleep history interviews,
6 sleep diaries, actigraphy, and/or Multiple Sleep Latency Test or Maintenance of Wakefulness test
7 would be valuable tools in determining whether these groups share all the diagnostic features of
8 each PSD.
9
10
11
12
13
14
15

16
17
18
19
20 The findings from the present study should be viewed with limitations in mind. There was no control
21 group to determine the extent to which the four phenotypes exist in the general population. That
22 said, with 6-10% of the population meeting diagnostic criteria for insomnia⁵⁷ and 5% meeting
23 diagnostic criteria for hypersomnia⁵⁸ the present data do not reflect this with 213 of the 239 (89.1%)
24 participants, without apnoea or PLMS, meeting at least one quantitative criteria for insomnia or
25 hypersomnia. It could also be argued that a single night of polysomnography may not be enough to
26 capture the sleep of patients with CFS due to the first-night-effect⁴⁵. The first-night-effect is a
27 commonly observed response to the first night of sleeping in an unusual environment, such as a
28 sleep laboratory, whereby aspects of sleep can be affected. That said, where Le Bon and colleagues
29 demonstrated significant differences between nights one and two in a cohort of individuals with CFS,
30 these differences were not largely evident in the sleep architecture and many differences in the
31 sleep continuity variables disappeared after those with psychiatric illnesses were excluded from the
32 analysis. Interestingly, over 25% of Le Bon et al's⁴⁵ sample also demonstrated an 'inverse first-night-
33 effect' whereby they slept better on the first night compared to the second. This issue of the first-
34 night-effect in CFS is further complicated by other studies which have shown no such effect in this
35 population³¹. It is likely that inconsistencies in the first-night-effect reflect typical night-to-night
36 variability⁵⁹⁻⁶¹ in addition to situation-specific factors, such as acclimating to a new environment,
37 relating to the PSG on the first and second nights. What would be ideal, albeit expensive, is a PSG
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 study over several nights (e.g. at least fourteen continuous nights are suggested for insomnia⁶²) to
4
5 ensure these issues are accounted for. That said, what may be more practical is to determine how
6
7 information from the present study can inform, in conjunction with other assessments, actual
8
9 clinical practice. One suggestion is, ideally after ruling out PSDs, individuals should be interviewed
10
11 about their sleep (usually over the last month) and provide a sleep diary. This information would
12
13 provide a subjective account that could be matched to the four phenotypes (as in Table 3) to inform
14
15 treatment.
16
17
18
19
20

21
22 Overall, the results suggest a significant overlap between CFS and a variety of symptoms of sleep
23
24 disturbance. One night of PSG is sufficient to tease apart, and exclude, those with apnoea and
25
26 periodic limb movement disorders from four other distinct sleep phenotypes in patients with CFS.
27
28 Interestingly, these four phenotypes tend to mirror symptoms related to sleep quality and quantity
29
30 that are amenable to different treatment strategies. As such, clinicians tailoring sleep-based
31
32 interventions for patients with CFS should be mindful of these phenotypes.
33
34
35
36
37

38 Contributions – All authors (JGE, ZMG, VD, JLN, PdR, DD) were involved in the design of the study.
39
40 PdR and DD conducted the study and JGE and ZMG analysed the data. The first draft was written by
41
42 JGE, JLN, VD and ZMG and was edited by all authors. All authors approved the final version of the
43
44 manuscript.
45
46
47
48

49 Funding – This research was not funded
50
51
52
53

54 Competing Interests – None
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Provenance and peer review – Not commissioned; externally peer reviewed

Data sharing statement – No additional data are available

For peer review only

REFERENCES

- (1) Fukuda, K., Straus, S. E., Hickie, I., et al. (1994). The chronic fatigue syndrome - a comprehensive approach to its definition and study. *Annals of Internal Medicine*, 121(12), 953-959.
- (2) Wessely, S., Chalder, T., Hirsch, S., et al. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: A prospective primary care study. *American Journal of Public Health*, 87(9), 1449-1455.
- (3) Jason L, Richman J, Rademaker A et al. (1999). A community based study of chronic fatigue syndrome. *Arch Intern Med*, 159: 2129–2137.
- (4) Reyes, M., Nisenbaum, R., Hoaglin, et al. (2003). Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. *Archives of internal medicine* 163(13), 1530-1536.
- (5) Kato, K., Sullivan, P. F., Evengard, B., et al. Premorbid predictors of chronic fatigue. *Archives of General Psychiatry*, 63(11), 1267-1272.
- (6) Taylor R, Jason L (2001). Sexual abuse, physical abuse, chronic fatigue, and chronic fatigue syndrome: a community-based study. *J Nerv Ment Dis* 189: 709–715.
- (7) Harvey, S. B., Wadsworth, M., Wessely, S., & Hotopf, M. (2008). Etiology of chronic fatigue syndrome: testing popular hypotheses using a national birth cohort study. *Psychosomatic Medicine*, 70(4), 488-495.
- (8) Deary, V. & Chalder, T. (2010). Personality and perfectionism in chronic fatigue syndrome: a closer look. *Psychology & Health*, 25(4), 465-475.
- (9) Buchwald, D. S., Rea, T. D., Katon W. J., et al. Acute infectious mononucleosis: characteristics of patients who report failure to recover. *The American Journal of Medicine*, 109 (7), 531-537.
- (10) Hatcher, S. & House, A. (2003). Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study. *Psychological Medicine*, 33(7), 1185-1192.

- 1
2
3 (11) Gaab, J., Rohleder, N., Heitz, V., et al. (2005). Stress-induced changes in LPS-induced pro-
4
5 inflammatory cytokine production in chronic fatigue syndrome. *Psychoneuroendocrinology*,
6
7 30, 188–198.
8
9
10 (12) Cho H. J., Hotopf, M., & Wessely, S. (2005). The placebo response in the treatment of chronic
11
12 fatigue syndrome: a systematic review and meta-analysis. *Psychosomatic Medicine*, 67(2),
13
14 301-13.
15
16 (13) Nijs, J., Meeus, M., Van Oosterwijck, J., et al. (2012). In the mind or in the brain? Scientific
17
18 evidence for central sensitisation in chronic fatigue syndrome. *European Journal of Clinical*
19
20 *Investigation*, 42(2), 203-212.
21
22 (14) Meeus, M., & Nijs, J. (2007). Central sensitization: a biopsychosocial explanation for chronic
23
24 widespread pain in patients with fibromyalgia and chronic fatigue syndrome. *Clinical*
25
26 *Rheumatology*, 26(4), 465-473.
27
28 (15) Jones, D. E., Hollingsworth, K. G., Taylor, R., et al. (2010).
29
30 Abnormalities in pH handling by peripheral muscle and potential regulation by the
31
32 autonomic nervous system in chronic fatigue syndrome. *Journal of Internal Medicine*, 267(4),
33
34 394-401.
35
36 (16) Newton, J. L., Pairman, J., Hallsworth, K., et al. Physical
37
38 activity intensity but not sedentary activity is reduced in chronic fatigue syndrome and is
39
40 associated with autonomic regulation. *International Journal of Medicine*, 104(8), 681-687.
41
42 (17) Candy, J. V., Meyer, A. W., Poggio, A. J., & Guidry, B. L. (2004). Time-reversal processing for an
43
44 acoustic communications experiment in a highly reverberant environment. *The Journal of*
45
46 *the Acoustical Society of America*, 115(4), 1621-1631.
47
48 (18) Moss-Morris R, Spence M, Hou R (2010). The pathway from glandular fever to chronic fatigue
49
50 syndrome: can the cognitive behavioural model provide the map? *Psychol Med*, 41(5), 1099-
51
52 101.
53
54
55
56
57
58
59
60

- 1
2
3 (19) Moss-Morris, R., Deary, V. & Castell, B. (2012). Chronic Fatigue Syndrome. Chapter 25 In:
4 Barnes, M. P., & Good, D. C. (Eds.). (2012). *Neurological Rehabilitation: Handbook of Clinical*
5 *Neurology* (Series Editors: Aminoff, Boller and Swaab) (Vol. 110). Elsevier.
6
7
8
9
10 (20) Komaroff, A. L., & Buchwald, D. (1991). Symptoms and signs of chronic fatigue syndrome.
11 *Reviews of infectious diseases, 13 Suppl 1, S8-11.*
12
13 (21) Manu, P., Lane, T. J., & Matthews, D. A. (1988). The frequency of the chronic fatigue syndrome
14 in patients with symptoms of persistent fatigue. *Annals of Internal Medicine, 109(7), 554-*
15 *556.*
16
17
18
19
20 (22) Gotts, Z. M. Unpublished PhD Thesis
21
22 (23) Nisenbaum, R., Jones, J. F., Unger, E. R., et al. A population-based study of the clinical course of
23 chronic fatigue syndrome. *Health and Quality of Life Outcomes, 1, 49.*
24
25
26 (24) Turner, T. H., Drummond, S., Salamat, J. S., & Brown, G. G. (2007). Effects of 42 hr of total sleep
27 deprivation on component processes of verbal working memory. *Neuropsychology, 21(6),*
28 *787.*
29
30
31
32 (25) Van Cauter, E., Leproult, R., & Plat, L. (2000). Age-related changes in slow wave sleep and REM
33 sleep and relationship with growth hormone and cortisol levels in healthy men. *JAMA: the*
34 *journal of the American Medical Association, 284(7), 861-868.*
35
36
37
38 (26) Stickgold, R. (2005). Sleep-dependent memory consolidation. *Nature, 437(7063), 1272-1278.*
39
40
41 (27) Roberts, A. D. L., Wessely, S., Chalder, T., et al. Salivary
42 cortisol response to awakening in chronic fatigue syndrome. *British Journal of Psychiatry,*
43 *184, 136-141.*
44
45
46
47 (28) Buchwald, D., Pascualy, R., Bombardier, C., & Kith, P. (1994). Sleep disorders in patients with
48 chronic fatigue. *Clinical infectious diseases : an official publication of the Infectious Diseases*
49 *Society of America, 18(1), S68-72.*
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (29) Krupp, L. B., Jandorf, L., Coyle, P. K., & Mendelson, W. B. (1993). Sleep disturbance in chronic
4
5 fatigue syndrome. *Journal of Psychosomatic Research*, 37(4), 325-331.
6
7 (30) Manu, P., Lane, T. J., Matthews, D. A., et al. Alpha-delta sleep in patients with a chief complaint
8
9 of chronic fatigue. *Southern medical journal*, 87(4), 465-470.
10
11 (31) Whelton, C. L., Salit, I., & Moldofsky, H. (1992). Sleep, epstein-barr virus infection,
12
13 musculoskeletal pain, and depressive symptoms in chronic fatigue syndrome. *J Rheumatol*,
14
15 19(6), 939-943.
16
17 (32) Creti, L., Libman, E., Baltzan, M., et al. Impaired sleep in chronic fatigue syndrome how is it best
18
19 measured? *Journal of Health Psychology*, 15(4), 596-607.
20
21 (33) Decker, M. J., Tabassum, H., Lin, J. M. S., & Reeves, W. C. (2009). Electroencephalographic
22
23 correlates of chronic fatigue syndrome. *Behavioral and Brain Functions*, 5.
24
25 (34) Fossey, M., Libman, E., Bailes, S., et al. (2004). Sleep quality and psychological adjustment in
26
27 chronic fatigue syndrome. *Journal of Behavioral Medicine*, 27(6), 581-605.
28
29 (35) Kishi, A., Natelson, B. H., Togo, F., et al. Sleep
30
31 stage transitions in chronic fatigue syndrome patients with or without fibromyalgia. *Conf*
32
33 *Proc IEEE Eng Med Biol Soc*, 1, 5391-5394.
34
35 (36) Watson, N. F., Jacobsen, C., Goldberg, J., et al. Subjective and objective sleepiness in
36
37 monozygotic twins discordant for chronic fatigue syndrome. *Sleep*, 27(5), 973-977.
38
39 (37) Armitage, R., Landis, C., Hoffmann, R., et al. (2007). The impact of a 4-hour sleep delay on slow
40
41 wave activity in twins discordant for chronic fatigue syndrome. *Sleep*, 30(5), 657-662.
42
43 (38) Ball, N., Buchwald, D. S., Schmidt, D., et al. Monozygotic twins discordant for chronic fatigue
44
45 syndrome - objective measures of sleep. *Journal of Psychosomatic Research*, 56(2), 207-212.
46
47 (39) Fischler, B., LeBon, O., Hoffmann, G., et al. Sleep anomalies in the chronic fatigue syndrome - a
48
49 comorbidity study. *Neuropsychobiology*, 35(3), 115-122.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (40) Majer, M., Jones, J. F., Unger, E. R., et al. (2007). Perception versus polysomnographic
4
5 assessment of sleep in cfs and non-fatigued control subjects: Results from a population-
6
7 based study. *BMC Neurology*, 7.
8
9
10 (41) Reeves, W. C., Heim, C., Maloney, E. M., et al. (2006). Sleep characteristics of persons with
11
12 chronic fatigue syndrome and non-fatigued controls: Results from a population-based study.
13
14 *BMC Neurology*, 6.
15
16 (42) Stores, G., Fry, A., & Crawford, C. (1998). Sleep abnormalities demonstrated by home
17
18 polysomnography in teenagers with chronic fatigue syndrome. *Journal of Psychosomatic*
19
20 *Research*, 45(1), 85-91.
21
22 (43) Van Hoof, E., De Becker, P., Lapp, C., et al. Defining the occurrence and influence of alpha-delta
23
24 sleep in chronic fatigue syndrome. *American Journal of the Medical Sciences*, 333(2), 78-84.
25
26 (44) Watson, N. F., Kapur, V., Arguelles, et al. (2003). Comparison of subjective and objective
27
28 measures of insomnia in monozygotic twins discordant for chronic fatigue syndrome. *Sleep*,
29
30 26(3), 324-328.
31
32 (45) Le Bon, O., Minner, P., Van Moorsel, C., et al. (2003). First-night effect in the chronic fatigue
33
34 syndrome. *Psychiatry Research*, 120(2), 191-199.
35
36 (46) Le Bon, O., Neu, D., Valente, F., & Linkowski, P. (2007). Paradoxical nrems distribution in "pure"
37
38 chronic fatigue patients: A comparison with sleep apnea-hypopnea patients and healthy
39
40 control subjects. *Journal of Chronic Fatigue Syndrome*, 14(2), 45-60.
41
42 (47) Morriss, R., Sharpe, M., Sharpley, A. L., et al. Abnormalities of sleep in patients with the chronic
43
44 fatigue syndrome. *British Medical Journal*, 306(6886), 1161-1164.
45
46 (48) Sharpley, A., Clements, A., Hawton, K., & Sharpe, M. (1997). Do patients with "pure" chronic
47
48 fatigue syndrome (neurasthenia) have abnormal sleep? *Psychosomatic Medicine*, 59(6), 592-
49
50 596.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (49) Togo, F., Natelson, B. H., Cherniack, N. S., et al. Sleep structure and sleepiness in chronic fatigue
4
5 syndrome with or without coexisting fibromyalgia. *Arthritis Research & Therapy*, 10(3).
6
7 (50) Guilleminault, C., Poyares, D., da Rosa, A., et al. Chronic fatigue, unrefreshing sleep and
8
9 nocturnal polysomnography. *Sleep Medicine*, 7(6), 513-520.
10
11 (51) Rahman, K. B., A. Galbraith, S. Lloyd, A. & Vollmer-Conna, U. (2011). Sleep-wake behavior in
12
13 chronic fatigue syndrome. *Sleep*, 34(5), 671-678.
14
15 (52) American Academy of Sleep Medicine. (2007) *The AASM manual for the scoring of sleep and*
16
17 *associated events : rules, terminology and technical specifications*. Washington DC. Author.
18
19 (53) Carskadon, M. & Dement, W.C. (2011). Normal human sleep: An overview. Chapter 2 In Kryger,
20
21 M.H., Roth, T. & Dement, W.C. *Principles and Practice of Sleep Medicine* (5th Edition).
22
23 Elsevier: Missouri.
24
25 (54) Edinger, J. D., Bonnet, M. H., Bootzin, R. R., et al. (2004). Derivation of research diagnostic
26
27 criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. *Sleep*,
28
29 27(8), 1567-1596.
30
31 (55) Dündar, Y., Dodd, S., Strobl, J., et al. Comparative efficacy of newer hypnotic drugs for the
32
33 short-term management of insomnia: a systematic review and meta-analysis. *Human*
34
35 *Psychopharmacology: Clinical and Experimental*, 19(5), 305-322.
36
37 (56) Brandenberger, G., Buchheit, M., Ehrhart, J., et al. Is slow wave sleep
38
39 an appropriate recording condition for heart rate variability analysis? *Autonomic*
40
41 *Neuroscience*, 121(1), 81-86.
42
43 (57) Dauvilliers, Y. (2006). Differential diagnosis in hypersomnia. *Current neurology and neuroscience*
44
45 *reports*, 6(2), 156-162.
46
47 (58) Ohayon, M. M. (2002). Epidemiology of insomnia: what we know and what we still need to
48
49 learn. *Sleep medicine reviews*, 6(2), 97-111.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (59) Buysse, D. J., Cheng, Y., Germain, A., et al. (2010). Night-to-night sleep variability in older adults
4
5 with and without chronic insomnia. *Sleep medicine*, 11(1), 56.
6
7 (60) Perlis, M.L., Swinkles, C.M., Gherman, P.R., et al. The incidence and temporal patterning of
8
9 insomnia: a pilot study. *Journal of Sleep Research*, 19(1), 31-35.
10
11 (61) Vallieres, A., Ivers, H., Beaulieu-Bonneau, S. & Morin, C.M. (2011). Predictability of Sleep in
12
13 Patients with Insomnia. *Sleep*, 34(5), 609-617.
14
15 (62) Wohlgemuth, W.K., Edinger, J.D., Fins, A.I. & Sullivan, R.J. (1999). How many nights are enough?
16
17 The short-term stability of sleep parameters in elderly insomniacs and normal sleepers.
18
19 *Psychophysiology*, 36(2), 233-244.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 Are there sleep-specific phenotypes in patients with Chronic Fatigue Syndrome? A cross-sectional
8
9 Polysomnography analysis
10

11
12 Zoe M. Gotts MSc^a, Vincent Deary PhD^a, Julia Newton MD^b, Donna van der Dussen MD^c, Pierre de
13
14 Roy MD^c, Jason G. Ellis PhD^{a*}
15

16
17
18 * Corresponding Author
19 Dr Jason G Ellis
20 Northumbria Centre for Sleep Research
21 School of Life Sciences
22 Northumbria University
23 138 Northumberland Building
24 Newcastle-upon-Tyne
25 NE1 8ST
26 Jason.ellis@northumbria.ac.uk
27 +44(0)1912273081
28
29
30
31
32
33
34
35
36

- 37
38 a) Northumbria Centre for Sleep Research, Northumbria University, Newcastle, UK
39 b) Institute for Ageing and Health, Newcastle University, Newcastle, UK
40 c) VermoeidheidCentrum Nederland bv, Lelystad, Netherlands
41
42
43
44
45
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7 ABSTRACT

8
9 Objectives: Despite sleep disturbances being a central complaint in patients with Chronic Fatigue
10 Syndrome (CFS), evidence of objective sleep abnormalities, from over 30 studies, is inconsistent. The
11 present study aimed to identify whether sleep-specific phenotypes exist in CFS and explore objective
12 characteristics that could differentiate phenotypes, whilst also being relevant to routine clinical
13 practice.
14
15

16
17
18
19 Design: A cross-sectional, single-site, study.
20

21
22 Setting: A fatigue clinic in the Netherlands
23

24
25 Participants: A consecutive series of 343 ~~otherwise healthy~~ patients meeting criteria for CFS,
26 according to the Fukuda definition.
27
28

29
30 Measures: Patients underwent a single night of polysomnography (all-night recording of
31 Electroencephalography, Electromyography, Electrooculography, Electrocardiogram and Respiration)
32 that were hand-scored by a researcher blind to diagnosis and patient history.
33
34

35
36 Results: Of the 343 patients, 104 (30.3%) were identified with a Primary Sleep Disorder explaining
37 their diagnosis. A hierarchical cluster analysis on the remaining 239 patients resulted in four sleep
38 phenotypes identified at saturation. Of the 239 patients, 89.1% met quantitative criteria for at least
39 one objective sleep problem. A one-way ANOVA confirmed distinct sleep profiles for each sleep
40 phenotype. Relatively longer sleep onset latencies, longer Rapid Eye Movement (REM) latencies, and
41 smaller percentages of both Stage 2 and REM characterized the first phenotype. The second
42 phenotype was characterised by more frequent arousals per hour. The third phenotype was
43 characterised by a longer Total Sleep Time, shorter REM Latencies, and a higher percentage of REM
44 and low percentage of wake time. The final phenotype had the shortest Total Sleep Time and the
45 highest percentage of wake time and wake after sleep onset.
46
47
48
49
50
51
52
53

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: The results highlight the need to routinely screen for Primary Sleep Disorders in clinical practice and tailor sleep interventions, based on phenotype, to patients presenting with CFS. The results are discussed in terms of matching patients' self-reported sleep to these phenotypes in clinical practice.

For peer review only

Article Focus

- Despite 85-90% of patients with CFS reporting unrefreshing sleep, previous research has been unable to reliably identify specific irregularities in objective sleep
- To explore the possibility that sleep problems in this population are not homogeneous and that several sleep-specific phenotypes exist in this population which are amenable to different treatment approaches

Key Messages

- Over 30% of individuals with CFS, met diagnostic criteria for Sleep Apnoea or Periodic Limb Movement Disorder that could explain their current diagnosis.
- The sleep in those with CFS, without Sleep Apnoea or Periodic Limb Movement Disorder, centred around four specific sleep-disturbed phenotypes with 89.1% demonstrating quantitative criteria for insomnia or hypersomnolence.
- Each sleep-phenotype in CFS comprised objective characteristics that could be assessed and differentiated using patient's self-reports in primary care.

Strengths and Limitations:

- This is the first study to suggest, and identify, specific sleep-phenotypes in a large sample of patients with CFS.
- The objective findings can be easily translated and applied in routine primary care.
- A limitation is the use of a single-night of Polysomnography.

INTRODUCTION

Chronic Fatigue Syndrome (CFS), as defined by the international consensus definition¹ is a condition characterised by profound fatigue, of definite onset, which has persisted for at least 6 months, and causes substantial disruption to the individual's daily functioning. In addition to fatigue, at least four other key symptoms are required to fulfil diagnostic criteria, including muscle and joint pain, headache, cognitive dysfunction and unrefreshing sleep. Thus defined, CFS affects between 0.23-2.6% of the adult population²⁻⁴. There are several theories as to the pathogenesis of CFS. However it is likely the development and maintenance of CFS is multifactorial. Predisposing factors include a general propensity to both emotional and physical distress, history of abuse, being more than usually physically active, and being perfectionist⁵⁻⁸. Precipitating events include viruses such as glandular fever and major life events⁹⁻¹⁰. Several factors appear to be involved in the maintenance of symptoms. Physiologically, evidence suggests dysregulation of the hypothalamic pituitary adrenal (HPA) axis, increased cytokine production and HPA responsiveness to cytokines¹¹⁻¹², [hypersensitivity in the Central Nervous System \(i.e. central sensitisation\)](#)¹³⁻¹⁴, and autonomic dysfunction¹⁵⁻¹⁶. Two studies also highlight the importance of illness beliefs and behaviours¹⁷⁻¹⁸. Individuals who adopt all or nothing coping styles in response to symptoms (i.e. push on through until they crash out) and attribute broad ranges of everyday symptoms to their illness are more likely to develop CFS post-virally. In sum, research suggests in CFS multiple processes in distinct domains, such as physiology, illness beliefs, inconsistent activity, sleep disturbance, medical uncertainty, and lack of guidance, can interact to maintain or exacerbate symptoms¹⁹.

As mentioned above, unrefreshing sleep is one key diagnostic characteristic of CFS¹. It is also one of the most common symptom complaints²⁰⁻²¹ with 87-95% of patients reporting sleep difficulties²² that do not improve over the course of the illness²³. Where the purpose of sleep is subject to intense debate, its importance to human health and well-being is undeniable. Examinations of individuals

1
2
3
4
5
6
7 deprived or restricted of sleep consistently demonstrate deteriorations in mood, cognition, and
8 performance²⁴. The purpose of each different sleep stage is also unclear although it is generally
9 agreed that the lighter stages of sleep (stage 1 sleep and stage 2 sleep) afford transitions between
10 wakefulness and sleep and then between slow wave sleep (SWS) and Rapid Eye Movement sleep
11 (REM). SWS and REM are believed to confer recuperative, restorative, and learning properties for
12 the individual (e.g. the secretion of growth hormone, consolidation of memory)²⁵⁻²⁶. Therefore, the
13 proportion of each sleep stage and timing of entry into each sleep stage, SWS and REM in particular,
14 are important for the long-term maintenance of human physical and mental health.
15
16
17
18
19
20
21
22

23 Symptoms such as unrefreshing sleep may not only be markers of CFS but may also serve to
24 maintain it. For instance there may be reciprocal links between sleep quality, sleep-wake regulation
25 and fatigue. There is evidence of this, for instance, studies have shown that adopting activity and
26 sleep management strategies improves HPA axis functioning as measured by cortisol levels²⁷. This
27 suggests further investigation of sleep disturbance of CFS is of more than academic importance but
28 may highlight new avenues for intervention. From a clinical perspective it is also important to study
29 sleep more thoroughly in CFS as it may highlight some areas of diagnostic ambiguity. For instance
30 previous studies have shown sleep disorders (notably obstructive sleep apnoea) are occasionally
31 identified during PSG assessments with CFS patient cohorts²⁸⁻³¹.
32
33
34
35
36
37
38
39
40
41

42 Although over 30 Polysomnographic (PSG) studies on individuals with CFS exist, conclusive
43 statements about the type of sleep abnormalities in this population are difficult. Few studies report
44 a full characterisation of both sleep continuity (the timing, efficiency, and amount of sleep obtained)
45 and sleep architecture (amount of each sleep or wake stage and the timing of transitions to each
46 sleep stage), with some studies providing no PSG data at all^{28, 32-36}. Moreover, reporting practices
47 differ widely making interpretation and comparisons difficult (e.g. studies report the percentage of
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 each sleep and wake stage as an index of Sleep Period Time, Total Sleep Time or even Time in Bed³⁰⁻
8 ^{31; 37-44} whilst others report minutes of each stage⁴⁵⁻⁴⁹. What can be concluded from previous PSG
9
10 studies is in each study deviations from 'normal sleep' exist but there is no consistent pattern. For
11
12 example, where two studies⁴⁵⁻⁴⁶ report poor sleep efficiencies and 'normal range' REM latencies,
13
14 others^{37-38,46} found 'normal range' sleep efficiencies and short REM latencies and others still report a
15
16 normal sleep efficiency and a long REM latency⁴² or poor sleep efficiency and long REM latencies⁴⁹.
17
18 Moreover, the picture remains unclear after controlling for the severity of patients' self-reported
19
20 sleep complaints⁵⁰⁻⁵¹. Although differences in protocol, definitional criteria, and reporting criteria
21
22 may, to some extent, explain these differences, an alternative explanation is sleep difficulties in
23
24 individuals with CFS are not homogenous and various sleep phenotypes exist in this population.
25
26
27

28
29 To clarify the specific characterisation of sleep in CFS, the current study examined polysomnographic
30
31 data for a single night of sleep in a large group of CFS patients, to determine whether specific sleep
32
33 disturbances exist in this group, and if so, are these consistent across all patients.
34
35
36

37 METHOD

38
39 A cross-sectional, single-site, observational study was undertaken on a consecutive series of 343
40
41 patients (Mean age 37.21±12.42 years; 72 males 271 females) referred for a single-night
42
43 polysomnographic (PSG) study at a fatigue clinic in the Netherlands. The referral criteria for PSG
44
45 investigation were that the patient, a) met diagnostic criteria for CFS according the Fukuda definition
46
47 (1), b) they were drug-free for at least two-weeks prior to the overnight study, and c) their
48
49 symptoms could not be explained by a physical or psychological illness (e.g. anxiety or depression).
50
51 Patients gave informed consent to take part in the study and then were interviewed and medically
52
53
54

1
2
3
4
5
6
7 screened for the referral criteria by a registered physician and a registered psychiatrist. [The Ethics](#)
8
9 [Committee for the School of Life Sciences at Northumbria University had approved the study.](#)
10

11
12
13 Patients arrived at the clinic two hours before normal bedtime for electrode placement and bio-
14 calibration. The PSG montage comprised a standard 10/20 (i.e. F₄-M₁, C₄-M₁, O₂-M₁ and C₂ with
15 backups at F₃-M₂, C₃-M₂, O₁-M₂ and F_{p2}). Additional channels were used for EOG (E₁ and E₂
16 referenced to M₂), EMG (chin and anterior tibialis placements), ECG, and airflow, effort, body
17 position, and oximetry (via pulse oximeter). Filter settings were set to American Academy of Sleep
18 Medicine⁵² guidelines (e.g. low 0.3Hz / high 35Hz for EEG and EOG) with a sampling rate of 500Hz.
19 Impedances were maintained below 5KΩ. Participants [slept in the laboratory overnight and](#) were
20 allowed to retire to bed when they wished and left to naturally wake in the morning. Scoring was
21 conducted manually by a registered BRPT certified technician at 30-second epochs, according to
22 AASM guidelines. The scorer was blind to the aims of the study. The mean recording period was just
23 over 8 hours (508.5 ± 63.11 minutes). Descriptions of all sleep variables are detailed in Table 1.
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 Table 1: Description of sleep variables

Total Sleep Time (minutes)	Amount of time asleep
Sleep Onset Latency (minutes)	Length of time from lights out to first episode of stage 2 sleep
Wake After Sleep Onset (minutes)	Number of minutes of recorded wake following first episode of stage 2 sleep
Number of Awakenings (over TSP)	Number of wake bouts following first episode of stage 2 sleep
Number of Arousals	Number of arousals over the entire sleep period
Sleep Efficiency	Percentage of overall time spent in bed asleep
REM Latency	Length of time to first REM stage
AHI Index	Number of apnoea or hypopnea events per hour of sleep
% N1 (of TST)	Percentage of recorded stage 1 sleep over the total time asleep
% N2 (of TST)	Percentage of recorded stage 2 sleep over the total time asleep
% N3 (of TST)	Percentage of recorded slow wave sleep over the total time asleep
% REM (of TST)	Percentage of recorded Rapid Eye Movement sleep over the total time asleep
% WAKE (of TSP)	Percentage of recorded wake over the whole sleep period (from lights out to lights on)

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53 [Analytic Strategy](#)
54
55
56
57
58
59
60

A hierarchical Cluster Analysis was used to determine the number of phenotypes within the present sample after excluding those with Sleep Apnoea or Periodic Limb Movement Disorder. Cluster analysis is a data reduction technique that examines patterns amongst a set of variables to form homogenous groups. The Euclidean squared distance measure of similarity method was chosen for the cluster analysis as it uses the progressive distance between variables to form the groups and does not rely upon standardised data. As cluster analysis can be affected by multicollinearity, a correlation matrix was used to exclude variables that were highly correlated with one another. A One-Way Analysis Of Variance (ANOVA) was used to examine which of the sleep variables differentiated the phenotypes.

RESULTS

An initial examination of the Apnoea Hypopnoea Index (AHI) and Periodic Limb Movements (PLM's) indices indicated that 104 (43 males and 61 females) of the original 343 referrals (30.3%) met AASM criteria for either sleep apnoea (AHI ≥ 15 ; n = 101) or a periodic limb movement disorder (PLMs ≥ 5 ; n =17) (14 participants met criteria for both disorders). The overall sleep profile of the remaining 239 patients (Mean Age 34.4 \pm 11.84; 210 females and 29 males) was highly variable indicating the presence of phenotypes (Figure 1).

Insert Figure 1 Here

A hierarchical cluster analysis, using Ward's method, was undertaken to determine the number of groups (clusters) within the remaining 239 patients. Prior to the cluster analysis a correlation matrix was examined to avoid multicollinearity influencing the cluster model. On this basis four variables

1
2
3
4
5
6
7 were excluded (Height, Weight, Sleep Efficiency, and number of Spontaneous Arousals per hour) for
8
9 having correlation coefficients with one or more variables above $r = .8$. The final grouping variables
10
11 included in the cluster analysis were; age, sex, BMI, AHI's, PLM index, Number of Awakenings,
12
13 Number of Arousals per hour, Total Sleep Time (TST), Sleep Latency (SL), Wake After Sleep Onset
14
15 (WASO), percentage of %N1 (stage 1 sleep) of TST, %N2 (stage 2 sleep) of TST, %N3 (SWS) of TST,
16
17 %WAKE of TST, %REM of TST, and REM Latency (REML). The Euclidean squared distance measure of
18
19 similarity was used to group patients according to the included variables.

20
21
22
23 There were 6 clustering iterations overall (going from 8 clusters to 2). The fourth iteration was
24
25 chosen as saturation point as it was where the agglomeration schedule and dendrogram had the
26
27 highest reduction in the number of groupings (from six groups to four groups = reduction of 33%)
28
29 whilst retaining at least 5% of the total sample size in each group (i.e. $n \geq 11$). This latter rule was
30
31 chosen to afford sufficient power for inferential data analysis to occur.

32
33
34
35 A one-way ANOVA was undertaken on the four groups to determine which sleep variables
36
37 significantly differentiated the groups. There were no overall differences between the groups on age

38
39 ~~($F(3,235) = 1.95, p = .12$) or BMI ($F(3,235) = .82, p = .48$), but a significant sex difference was observed~~
40
41 ~~($\chi^2(3) = 10.54, p < .02$).~~ On inspection of the sex frequencies in each group, there was a significantly
42
43 higher ratio of males to females ~~(35.71% male)~~ in the first group compared to the other three groups
44
45 ~~(17.65%, 9.59%, and 4.17% male respectively). However, as two groups contained less than 5 males~~
46
47 ~~this could not be tested statistically, although due to the number of males in the overall sample~~
48
49 ~~(12.13%) this is likely to be artefact.~~ In relation to the polysomnography variables there were no
50
51 group differences in the number of arousals per hour or AHI index scores (PLMs were not included as
52
53
54
55
56
57
58
59
60

less than 10% of the total sample had a PLM index), but significant differences were observed on all the other sleep variables (Table 2).

Table 2: Characteristics of sample of individuals with CFS

Grouped Variable Clusters	Group 1 (N = 14)	Group 2 (N = 55)	Group 3 (N = 146)	Group 4 (N = 24)	F	p
Demographics						
Age	35.79 (12.39)	37.29 (12.72)	32.99 (10.82)	35.54 (14.49)	1.95	n.s.
Sex	5 Males (35.71%)	10 Males (17.65%)	14 Males (9.59%)	1 Male (4.17%)	**	**
BMI	24.86 (5.68)	23.85 (4.63)	23.41 (4.03)	22.81 (3.86)	0.82	n.s.
Sleep Variables						
Total Sleep Time (minutes)	270.95 (41.85)ab	387.03 (46.1)acd	473.21 (45.82)bce	264.15 (74.43)de	188.07	p<.001
Sleep Onset Latency (minutes)	107.79 (42.09)abc	30.97 (29.13)ad	19.17 (14.71)bd	28.94 (27.54)c	67.26	p<.001
Wake After Sleep Onset (minutes)	75.79 (39.35)ab	82.12 (45.25)cd	35.45 (25.39)ace	180.2 (58.48)bde	119.74	p<.001
Number of Awakenings (over TSP)	15.21 (8.06)	14.75 (11.62)ab	9.54 (5.85)a	16.96 (9.26)b	10.52	p<.001
Number of Arousals	3.57 (9.21)	10.91 (23.01)	6.2 (15.26)	1.38 (4.13)	2.24	n.s.
REM Latency	173.22 (55.03)abc	57.71 (34.31)ad	47.01 (28.22)be	84.46 (48.21)cde	63	p<.001
AHI Index	3.43 (3.46)	4.58 (4.39)	4.73 (4.04)	3.54 (4.19)	0.92	n.s.
% N1 (of TST)	21.84 (13.36)a	14.35 (9.14)b	12.55 (7.37)ac	24.22 (14.82)bc	14.15	p<.001
% N2 (of TST)	27.57 (13.15)ab	38.82 (12.36)a	38.44 (12.14)b	36.95 (13.66)	3.46	p<.02
% N3 (of TST)	44.46 (20.45)abc	31.07 (11.05)a	31.78 (12.41)b	29.28 (16.42)c	4.64	p<.004
% REM (of TST)	6.11 (4.58)abc	15.16 (5.47)ad	17.19 (5.57)be	9.65 (6.35)cde	26.46	p<.001
% WAKE (of TSP)	60.32 (21.09)abc	25.75 (11.61)ade	11.03 (6.16)bdf	75.26 (22.92)cef	271.62	p<.001

Notes

Letters sharing the same subscript are significantly different

**Statistical tests of between-group sex differences could not be performed due to the small number of men in each group

First Phenotype

The first phenotype comprised 14 patients with the longest Sleep Onset and REM Latencies and the highest percentage of SWS. Moreover, this group had the lowest percentages of both Stage 2 sleep and REM sleep. Statistically; this phenotype differed from the other three groups in terms of longer Sleep Onset and REM latencies, and a lower percentage of REM.

Second Phenotype

The second phenotype comprised 55 patients with the highest percentage of Stage 2 sleep and the highest number of arousals per hour although neither of these variables statistically separated them from all three other phenotypes.

Third Phenotype

1
2
3
4
5
6
7 The third phenotype comprised 146 patients with the highest Total Sleep Time and percentage of
8 REM. Additionally, this group demonstrated the shortest Sleep Onset and REM Latencies, lowest
9 wake after sleep onset and percentages of wake time and Stage 1 sleep, and the lowest number of
10 awakenings. Statistically, Total Sleep Time, percentage wake, and wake after sleep onset
11 differentiated this phenotype from each of the others.
12
13
14

15 16 17 *Fourth Phenotype*

18
19 The fourth phenotype comprised 24 patients who demonstrated the highest wake after sleep onset,
20 percentages of wake and Stage 1 sleep, and the highest number of awakenings. This group were also
21 the lowest in terms of Total Sleep Time, number of arousals per hour, and percentage of SWS.
22
23 Statistically, only wake after sleep onset and percentage of wake differentiated this group from each
24 of the others.
25
26
27
28
29
30
31

32 DISCUSSION

33
34 The aim of the study was to determine whether specific sleep phenotypes existed in patients with
35 CFS. A large consecutive series of patients, meeting criteria for CFS, underwent a single night of
36 polysomnography to determine the presence or absence of distinct sleep phenotypes. The first
37 finding, over 30% of individuals meeting diagnostic criteria for CFS also demonstrated a Primary
38 Sleep Disorder (sleep apnoea or PLMD) is important and underscores the need to assess for Primary
39 Sleep Disorders (PSDs) in CFS populations. As recommended treatment strategies for some PSDs
40 differ considerably from those for CFS (e.g. Continuous Positive Airway Pressure for apnoea vs. sleep
41 management strategies in CFS) it is important to direct the individual to, or adjunct, appropriate care
42 pathways as soon as possible. This finding also questions the ability to differentiate fatigue
43 associated with sleep apnoea or PLMD from that associated with CFS. Here family members and/or
44
45
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7 carers may be helpful for diagnosis sensitivity as they are likely to be aware of nocturnal breathing
8 disturbances (i.e. heavy snoring, gasping or pauses in breathing).
9

10
11
12
13 The overall PSG results (after excluding sleep apnoea and PLMD) confirm objective sleep difficulties
14 in patients with CFS. When comparing percentages of each sleep stage in 'normal' adult sleepers (i.e.
15 $\leq 5\%$ wake, between 2-5% stage 1, between 45-55% stage 2, between 13-23% SWS, and between 20-
16 25% REM⁵³) to the present sample this group fall outside the range on all these variables. The
17 present sample are spending more time awake and in the lighter stages of sleep (stage 1 and 2
18 sleep), and less time in deeper sleep stages of sleep (i.e. stage 2 sleep and SWS) and in REM. Further,
19 using the quantitative benchmarks of sleep disturbance outlined by Edinger⁵⁴ it can be seen that
20 where sleep efficiency and sleep latencies appear to be on the cusp of 'normal' sleep in the present
21 sample (85% sleep efficiency is considered normal and a sleep latency of ≥ 30 denotes a sleep
22 problem), wake after sleep onset appears to be almost twice as long as is considered problematic
23 (≥ 30 minutes tends to denote a sleep problem). Together, these findings indicate that sleep is an
24 objectively verifiable problem for patients with CFS that should be addressed clinically.
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 The cluster analysis identified, at saturation, four sleep phenotypes. The dendrogram identified two
40 groups partially related (i.e. groups one and four) and two that were largely independent (i.e. groups
41 two and three). This configuration was confirmed by the ANOVA showing statistically significant
42 differences in sleep continuity and architecture variables between the groups. That said, where
43 statistical significance and relative characterisation (e.g. highest in variable WX and Y and lowest in
44 variable Z) are important in understanding between-group differences the more salient question is
45 whether these four groups are clinically relevant in terms of specific sleep treatments in patients
46 with CFS. The use of different pharmacological agents (benzodiazepines, z-hypnotics, or stimulants)
47
48
49
50
51
52
53
54

or therapeutic interventions (i.e. Cognitive Behavioural Therapy for Insomnia or behavioural modification strategies) has been shown to have differential effects on specific aspects of sleep continuity and architecture. For example, zolpidem appears to have a better impact on the number of awakenings and perceived quality of sleep compared to nitrazepam, and lormetazepam appears better in reducing sleep latencies than zopiclone⁵⁵. As such tailoring treatment options to the presenting sleep problems in this population is likely to be more effective (Table 3).

Table 3: Characteristics (statistical and phenomenological) of patients with CFS

Sleep Phenotype	Central Differential Features	Associated Diagnostic Features	How this may present subjectively
1	Long Sleep Onset Latency Long REM Latency High amounts of Slow Wave Sleep Low amounts of REM	Low amounts of Stage 2 Sleep	Problems in getting off to sleep but when asleep few awakenings. The Sleep that is obtained is of normal quality.
2		High number of arousals per hour High amounts of Stage 2 Sleep	No difficulties in getting off to sleep and few awakenings but feelings or evidence of a 'restless' nights sleep
3	High Total Sleep Time Low amounts of time awake during the night Low number of wake periods during the night	High amounts of REM Sleep Short Sleep Onset Latency Low number of Awakenings Short REM Latencies Low amounts of Stage 1 Sleep	No difficulties in getting off to sleep and few awakenings but feelings of being unrefreshed on waking despite a significant amount of time in bed asleep.
4	Highest number of wake periods during the night Highest amounts of time awake during the night	Low Total Sleep Time Low number of arousals per hour during the night Low amounts of Slow Wave Sleep	Short sleep duration and although no difficulties getting off to sleep lots of awakenings for significant periods of time. Also increased feelings of daytime sleepiness.

Another, albeit related, consideration is the presence within the final sample of PSDs for which PSG is either not routinely recommended or where stand-alone it is insufficient for a definitive diagnosis⁵². Most relevant to the present sample are insomnia disorder and hypersomnolence disorders. Interestingly, groups one and four appear to be characterised by insomnia-like symptoms (i.e. difficulties initiating sleep or maintaining sleep) whereas groups two and three appear to share overlapping characteristics with disorders characterised by poor sleep quality (Table 2). In relation to

1
2
3
4
5
6
7 group three there is some overlap with hypersomnolence disorders (the term hypersomnolence will
8 replace hypersomnia under the DSM-5) as 14 patients (9.59%) slept for nine hours or longer and
9 eight patients (5.48%) demonstrated the main polysomnographically defined symptom of narcolepsy
10 (i.e. a REM Latency of less than 15 minutes). For group two there is no obvious overlap with a
11 specific DSM-5-defined sleep disorder although as Stage 2 sleep has been associated with hormonal
12 and autonomic regulation⁵⁶ increased amounts are likely to relate to both higher levels of autonomic
13 and cortical arousal inhibiting deep sleep. As such, a PSG study with adjunct sleep history interviews,
14 sleep diaries, actigraphy, and/or Multiple Sleep Latency Test or Maintenance of Wakefulness test
15 would be valuable tools in determining whether these groups share all the diagnostic features of
16 each PSD.
17
18
19
20
21
22
23
24
25
26
27

28 The findings from the present study should be viewed with limitations in mind. There was no control
29 group to determine the extent to which the four phenotypes exist in the general population. That
30 said, with 6-10% of the population meeting diagnostic criteria for insomnia⁵⁷ and 5% meeting
31 diagnostic criteria for hypersomnia⁵⁸ the present data do not reflect this with 213 of the 239 (89.1%)
32 participants, without apnoea or PLMS, meeting at least one quantitative criteria for insomnia or
33 hypersomnia. It could also be argued that a single night of polysomnography may not be enough to
34 capture the sleep of patients with CFS due to the first-night-effect⁴⁵. The first-night-effect is a
35 commonly observed response to the first night of sleeping in an unusual environment, such as a
36 sleep laboratory, whereby aspects of sleep can be affected. That said, where Le Bon and colleagues
37 demonstrated significant differences between nights one and two in a cohort of individuals with CFS,
38 these differences were not largely evident in the sleep architecture and many differences in the
39 sleep continuity variables disappeared after those with psychiatric illnesses were excluded from the
40 analysis. Interestingly, over 25% of Le Bon et al's⁴⁵ sample also demonstrated an 'inverse first-night-
41 effect' whereby they slept better on the first night compared to the second. This issue of the first-
42
43
44
45
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7 night-effect in CFS is further complicated by other studies which have shown no such effect in this
8 population³¹. It is likely that inconsistencies in the first-night-effect reflect typical night-to-night
9 variability⁵⁹⁻⁶¹ in addition to situation-specific factors, such as acclimating to a new environment,
10 relating to the PSG on the first and second nights. What would be ideal, albeit expensive, is a PSG
11 study over several nights (e.g. at least fourteen continuous nights are suggested for insomnia⁶²) to
12 ensure these issues are accounted for. That said, what may be more practical is to determine how
13 information from the present study can inform, in conjunction with other assessments, actual
14 clinical practice. One suggestion is, ideally after ruling out PSDs, individuals should be interviewed
15 about their sleep (usually over the last month) and provide a sleep diary. This information would
16 provide a subjective account that could be matched to the four phenotypes (as in Table 3) to inform
17 treatment.
18
19
20
21
22
23
24
25
26
27
28
29

30 Overall, the results suggest a significant overlap between CFS and a variety of symptoms of sleep
31 disturbance. One night of PSG is sufficient to tease apart, and exclude, those with apnoea and
32 periodic limb movement disorders from four other distinct sleep phenotypes in patients with CFS.
33 Interestingly, these four phenotypes tend to mirror symptoms related to sleep quality and quantity
34 that are amenable to different treatment strategies. As such, clinicians tailoring sleep-based
35 interventions for patients with CFS should be mindful of these phenotypes.
36
37
38
39
40
41
42
43

44 Contributions – All authors (JGE, ZMG, VD, JLN, PdR, DD) were involved in the design of the study.

45 PdR and DD conducted the study and JGE and ZMG analysed the data. The first draft was written by

46 JGE, JLN, VD and ZMG and was edited by all authors. All authors approved the final version of the

47 manuscript.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Funding – This research was not funded

Competing Interests – None

Provenance and peer review – Not commissioned; externally peer reviewed

Data sharing statement – No additional data are available

For peer review only



REFERENCES

- (1) Fukuda, K., Straus, S. E., Hickie, I., et al. (1994). The chronic fatigue syndrome - a comprehensive approach to its definition and study. *Annals of Internal Medicine*, 121(12), 953-959.
- (2) Wessely, S., Chalder, T., Hirsch, S., Wallace, P., & Wright, D. (1997). The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: A prospective primary care study. *American Journal of Public Health*, 87(9), 1449-1455.
- (3) Jason L, Richman J, Rademaker A et al. (1999). A community based study of chronic fatigue syndrome. *Arch Intern Med*, 159: 2129–2137.
- (4) Reyes, M., Nisenbaum, R., Hoaglin, et al. (2003). Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. *Archives of internal medicine* 163(13), 1530-1536.
- (5) Kato, K., Sullivan, P. F., Evengard, B., & Pedersen, N. L. (2006). Premorbid predictors of chronic fatigue. *Archives of General Psychiatry*, 63(11), 1267-1272.
- (6) Taylor R, Jason L (2001). Sexual abuse, physical abuse, chronic fatigue, and chronic fatigue syndrome: a community-based study. *J Nerv Ment Dis* 189: 709–715.
- (7) Harvey, S. B., Wadsworth, M., Wessely, S., & Hotopf, M. (2008). Etiology of chronic fatigue syndrome: testing popular hypotheses using a national birth cohort study. *Psychosomatic Medicine*, 70(4), 488-495.
- (8) Deary, V. & Chalder, T. (2010). Personality and perfectionism in chronic fatigue syndrome: a closer look. *Psychology & Health*, 25(4), 465-475.
- (9) Buchwald, D. S., Rea, T. D., Katon W. J., Russo, J. E., & Ashley, R. L. (2000). Acute infectious mononucleosis: characteristics of patients who report failure to recover. *The American Journal of Medicine*, 109 (7), 531-537.

- 1
2
3
4
5
6
7 (10) Hatcher, S. & House, A. (2003). Life events, difficulties and dilemmas in the onset of chronic
8 fatigue syndrome: a case-control study. *Psychological Medicine*, 33(7), 1185-1192.
9
10 (11) Gaab, J., Rohleder, N., Heitz, V., et al. (2005). Stress-induced changes in LPS-induced pro-
11 inflammatory cytokine production in chronic fatigue syndrome. *Psychoneuroendocrinology*,
12 30, 188–198.
13
14 (12) Cho H. J., Hotopf, M., & Wessely, S. (2005). The placebo response in the treatment of chronic
15 fatigue syndrome: a systematic review and meta-analysis. *Psychosomatic Medicine*, 67(2),
16 301-13.
17
18 (13) Nijs, J., Meeus, M., Van Oosterwijck, J., et al. (2012). In the mind or in the brain? Scientific
19 [evidence for central sensitisation in chronic fatigue syndrome. *European Journal of Clinical*](#)
20 [*Investigation*, 42\(2\), 203-212.](#)
21
22 (14) Meeus, M., & Nijs, J. (2007). Central sensitization: a biopsychosocial explanation for chronic
23 [widespread pain in patients with fibromyalgia and chronic fatigue syndrome. *Clinical*](#)
24 [*Rheumatology*, 26\(4\), 465-473.](#)
25
26 (15) Jones, D. E., Hollingsworth, K. G., Taylor, R., Blamire, A. M., & Newton, J. L. (2010).
27 Abnormalities in pH handling by peripheral muscle and potential regulation by the
28 autonomic nervous system in chronic fatigue syndrome. *Journal of Internal Medicine*, 267(4),
29 394-401.
30
31 (16) Newton, J. L., Pairman, J., Hallsworth, K., Moore, S., Plotz, T., & Trenell, M. I. (2011). Physical
32 activity intensity but not sedentary activity is reduced in chronic fatigue syndrome and is
33 associated with autonomic regulation. *International Journal of Medicine*, 104(8), 681-687.
34
35 (17) Candy, J. V., Meyer, A. W., Poggio, A. J., & Guidry, B. L. (2004). Time-reversal processing for an
36 acoustic communications experiment in a highly reverberant environment. *The Journal of*
37 *the Acoustical Society of America*, 115(4), 1621-1631.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Formatted: Font: Italic

- 1
2
3
4
5
6
7 (18) Moss-Morris R, Spence M, Hou R (2010). The pathway from glandular fever to chronic fatigue
8 syndrome: can the cognitive behavioural model provide the map? *Psychol Med*, 41(5), 1099-
9 101.
10
11
12 (19) Moss-Morris, R., Deary, V. & Castell, B. (2012). Chronic Fatigue Syndrome. Chapter 25 In:
13 Barnes, M. P., & Good, D. C. (Eds.). (2012). *Neurological Rehabilitation: Handbook of Clinical*
14 *Neurology* (Series Editors: Aminoff, Boller and Swaab) (Vol. 110). Elsevier.
15
16 (20) Komaroff, A. L., & Buchwald, D. (1991). Symptoms and signs of chronic fatigue syndrome.
17 *Reviews of infectious diseases*, 13 Suppl 1, S8-11.
18
19 (21) Manu, P., Lane, T. J., & Matthews, D. A. (1988). The frequency of the chronic fatigue syndrome
20 in patients with symptoms of persistent fatigue. *Annals of Internal Medicine*, 109(7), 554-
21 556.
22
23 (22) Gotts, Z. M. Unpublished PhD Thesis
24
25 (23) Nisenbaum, R., Jones, J. F., Unger, E. R., Reyes, M., & Reeves, W. C. (2003). A population-based
26 study of the clinical course of chronic fatigue syndrome. *Health and Quality of Life*
27 *Outcomes*, 1, 49.
28
29 (24) Turner, T. H., Drummond, S., Salamat, J. S., & Brown, G. G. (2007). Effects of 42 hr of total sleep
30 deprivation on component processes of verbal working memory. *Neuropsychology*, 21(6),
31 787.
32
33 (25) Van Cauter, E., Leproult, R., & Plat, L. (2000). Age-related changes in slow wave sleep and REM
34 sleep and relationship with growth hormone and cortisol levels in healthy men. *JAMA: the*
35 *journal of the American Medical Association*, 284(7), 861-868.
36
37 (26) Stickgold, R. (2005). Sleep-dependent memory consolidation. *Nature*, 437(7063), 1272-1278.
38
39 (27) Roberts, A. D. L., Wessely, S., Chalder, T., Papadopoulos, A., & Cleare, A. J. (2004). Salivary
40 cortisol response to awakening in chronic fatigue syndrome. *British Journal of Psychiatry*,
41 184, 136-141.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


- 1
2
3
4
5
6
7 (28) Buchwald, D., Pascualy, R., Bombardier, C., & Kith, P. (1994). Sleep disorders in patients with
8 chronic fatigue. *Clinical infectious diseases : an official publication of the Infectious Diseases*
9 *Society of America*, 18(1), S68-72.
- 10
11 (29) Krupp, L. B., Jandorf, L., Coyle, P. K., & Mendelson, W. B. (1993). Sleep disturbance in chronic
12 fatigue syndrome. *Journal of Psychosomatic Research*, 37(4), 325-331.
- 13
14 (30) Manu, P., Lane, T. J., Matthews, D. A., Castriotta, R. J., Watson, R. K., & Abeles, M. (1994). Alpha-
15 delta sleep in patients with a chief complaint of chronic fatigue. *Southern medical journal*,
16 87(4), 465-470.
- 17
18 (31) Whelton, C. L., Salit, I., & Moldofsky, H. (1992). Sleep, epstein-barr virus infection,
19 musculoskeletal pain, and depressive symptoms in chronic fatigue syndrome. *J Rheumatol*,
20 19(6), 939-943.
- 21
22 (32) Creti, L., Libman, E., Baltzan, M., Rizzo, D., Bailes, S., & Fichten, C. S. (2010). Impaired sleep in
23 chronic fatigue syndrome how is it best measured? *Journal of Health Psychology*, 15(4), 596-
24 607.
- 25
26 (33) Decker, M. J., Tabassum, H., Lin, J. M. S., & Reeves, W. C. (2009). Electroencephalographic
27 correlates of chronic fatigue syndrome. *Behavioral and Brain Functions*, 5.
- 28
29 (34) Fossey, M., Libman, E., Bailes, S., et al. (2004). Sleep quality and psychological adjustment in
30 chronic fatigue syndrome. *Journal of Behavioral Medicine*, 27(6), 581-605.
- 31
32 (35) Kishi, A., Natelson, B. H., Togo, F., Struzik, Z. R., Rapoport, D. M., & Yamamoto, Y. (2010). Sleep
33 stage transitions in chronic fatigue syndrome patients with or without fibromyalgia. *Conf*
34 *Proc IEEE Eng Med Biol Soc*, 1, 5391-5394.
- 35
36 (36) Watson, N. F., Jacobsen, C., Goldberg, J., Kapur, V., & Buchwald, D. (2004). Subjective and
37 objective sleepiness in monozygotic twins discordant for chronic fatigue syndrome. *Sleep*,
38 27(5), 973-977.
- 39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 (37) Armitage, R., Landis, C., Hoffmann, R., et al. (2007). The impact of a 4-hour sleep delay on slow
8 wave activity in twins discordant for chronic fatigue syndrome. *Sleep*, 30(5), 657-662.
9
10 (38) Ball, N., Buchwald, D. S., Schmidt, D., Goldberg, J., Ashton, S., & Armitage, R. (2004).
11 Monozygotic twins discordant for chronic fatigue syndrome - objective measures of sleep.
12 *Journal of Psychosomatic Research*, 56(2), 207-212.
13
14 (39) Fischler, B., LeBon, O., Hoffmann, G., Cluydts, R., Kaufman, L., & DeMeirleir, K. (1997). Sleep
15 anomalies in the chronic fatigue syndrome - a comorbidity study. *Neuropsychobiology*, 35(3),
16 115-122.
17
18 (40) Majer, M., Jones, J. F., Unger, E. R., et al. (2007). Perception versus polysomnographic
19 assessment of sleep in cfs and non-fatigued control subjects: Results from a population-
20 based study. *BMC Neurology*, 7.
21
22 (41) Reeves, W. C., Heim, C., Maloney, E. M., et al. (2006). Sleep characteristics of persons with
23 chronic fatigue syndrome and non-fatigued controls: Results from a population-based study.
24 *BMC Neurology*, 6.
25
26 (42) Stores, G., Fry, A., & Crawford, C. (1998). Sleep abnormalities demonstrated by home
27 polysomnography in teenagers with chronic fatigue syndrome. *Journal of Psychosomatic*
28 *Research*, 45(1), 85-91.
29
30 (43) Van Hoof, E., De Becker, P., Lapp, C., Cluydts, R., & De Meirleir, K. (2007). Defining the
31 occurrence and influence of alpha-delta sleep in chronic fatigue syndrome. *American Journal*
32 *of the Medical Sciences*, 333(2), 78-84.
33
34 (44) Watson, N. F., Kapur, V., Arguelles, et al. (2003). Comparison of subjective and objective
35 measures of insomnia in monozygotic twins discordant for chronic fatigue syndrome. *Sleep*,
36 26(3), 324-328.
37
38 (45) Le Bon, O., Minner, P., Van Moorsel, C., et al. (2003). First-night effect in the chronic fatigue
39 syndrome. *Psychiatry Research*, 120(2), 191-199.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 (46) Le Bon, O., Neu, D., Valente, F., & Linkowski, P. (2007). Paradoxical nrems distribution in "pure"
8 chronic fatigue patients: A comparison with sleep apnea-hypopnea patients and healthy
9 control subjects. *Journal of Chronic Fatigue Syndrome*, 14(2), 45-60.
- 10
11
12 (47) Morriss, R., Sharpe, M., Sharpley, A. L., Cowen, P. J., Hawton, K., & Morris, J. (1993).
13 Abnormalities of sleep in patients with the chronic fatigue syndrome. *British Medical*
14 *Journal*, 306(6886), 1161-1164.
- 15
16
17 (48) Sharpley, A., Clements, A., Hawton, K., & Sharpe, M. (1997). Do patients with "pure" chronic
18 fatigue syndrome (neurasthenia) have abnormal sleep? *Psychosomatic Medicine*, 59(6), 592-
19 596.
- 20
21
22 (49) Togo, F., Natelson, B. H., Cherniack, N. S., FitzGibbons, J., Garcon, C., & Rapoport, D. M. (2008).
23 Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting
24 fibromyalgia. *Arthritis Research & Therapy*, 10(3).
- 25
26
27 (50) Guilleminault, C., Poyares, D., da Rosa, A., Kirisoglu, C., Almeida, T., & Lopes, M. C. (2006).
28 Chronic fatigue, unrefreshing sleep and nocturnal polysomnography. *Sleep Medicine*, 7(6),
29 513-520.
- 30
31
32 (51) Rahman, K. B., A. Galbraith, S. Lloyd, A. & Vollmer-Conna, U. (2011). Sleep-wake behavior in
33 chronic fatigue syndrome. *Sleep*, 34(5), 671-678.
- 34
35
36 (52) American Academy of Sleep Medicine. (2007) *The AASM manual for the scoring of sleep and*
37 *associated events : rules, terminology and technical specifications*. Washington DC. Author.
- 38
39
40 (53) Carskadon, M. & Dement, W.C. (2011). Normal human sleep: An overview. Chapter 2 In Kryger,
41 M.H., Roth, T. & Dement, W.C. *Principles and Practice of Sleep Medicine* (5th Edition).
42 Elsevier: Missouri.
- 43
44
45 (54) Edinger, J. D., Bonnet, M. H., Bootzin, R. R., et al. (2004). Derivation of research diagnostic
46 criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. *Sleep*,
47 27(8), 1567-1596.
- 48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 (55) Dündar, Y., Dodd, S., Strobl, J., Boland, A., Dickson, R., & Walley, T. (2004). Comparative efficacy
8 of newer hypnotic drugs for the short-term management of insomnia: a systematic review
9 and meta-analysis. *Human Psychopharmacology: Clinical and Experimental*, 19(5), 305-322.
- 10
11 (56) Brandenberger, G., Buchheit, M., Ehrhart, J., Simon, C., & Piquard, F. (2005). Is slow wave sleep
12 an appropriate recording condition for heart rate variability analysis? *Autonomic*
13 *Neuroscience*, 121(1), 81-86.
- 14
15 (57) Dauvilliers, Y. (2006). Differential diagnosis in hypersomnia. *Current neurology and neuroscience*
16 *reports*, 6(2), 156-162.
- 17
18 (58) Ohayon, M. M. (2002). Epidemiology of insomnia: what we know and what we still need to
19 learn. *Sleep medicine reviews*, 6(2), 97-111.
- 20
21 (59) Buysse, D. J., Cheng, Y., Germain, A., et al. (2010). Night-to-night sleep variability in older adults
22 with and without chronic insomnia. *Sleep medicine*, 11(1), 56.
- 23
24 (60) Perlis, M.L., Swinkles, C.M., Gherman, P.R., Pigeon, W.R., Matteson-Rusby, S.E., Jungvist, C. R.
25 (2009). The incidence and temporal patterning of insomnia: a pilot study. *Journal of Sleep*
26 *Research*, 19(1), 31-35.
- 27
28 (61) Vallieres, A., Ivers, H., Beaulieu-Bonneau, S. & Morin, C.M. (2011). Predictability of Sleep in
29 Patients with Insomnia. *Sleep*, 34(5), 609-617.
- 30
31 (62) Wohlgemuth, W.K., Edinger, J.D., Fins, A.I. & Sullivan, R.J. (1999). How many nights are enough?
32 The short-term stability of sleep parameters in elderly insomniacs and normal sleepers.
33 *Psychophysiology*, 36(2), 233-244.
- 34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Study Overview



Study Overview
119x90mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
X Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
X Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
X Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
X Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

X Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
X Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.